A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
A chronic form of cutaneous lupus erythematosus (LUPUS ERYTHEMATOSUS, CUTANEOUS) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterized by the presence of discoid skin plaques showing varying degrees of edema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur.
A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID).
Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Central nervous system vasculitis that is associated with SYSTEMIC LUPUS ERYTHEMATOSUS. Clinical manifestations may include DEMENTIA; SEIZURES; CRANIAL NERVE DISEASES; HEMIPARESIS; BLINDNESS; DYSPHASIA; and other neurological disorders.
A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN.
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
Endogenous tissue constituents that have the ability to interact with AUTOANTIBODIES and cause an immune response.
The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
A mouse substrain that is genetically predisposed to the development of systemic lupus erythematosus-like syndrome, which has been found to be clinically similar to the human disease. It has been determined that this mouse strain carries a mutation in the fas gene. Also, the MRL/lpr is a useful model to study behavioral and cognitive deficits found in autoimmune diseases and the efficacy of immunosuppressive agents.
A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B.
An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.
The protein components that constitute the common core of small nuclear ribonucleoprotein particles. These proteins are commonly referred as Sm nuclear antigens due to their antigenic nature.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
A type of lupus erythematosus characterized by deep dermal or subcutaneous nodules, most often on the head, face, or upper arms. It is generally chronic and occurs most often in women between the ages of 20 and 45.
Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES.
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.
A subcomponent of complement C1, composed of six copies of three polypeptide chains (A, B, and C), each encoded by a separate gene (C1QA; C1QB; C1QC). This complex is arranged in nine subunits (six disulfide-linked dimers of A and B, and three disulfide-linked homodimers of C). C1q has binding sites for antibodies (the heavy chain of IMMUNOGLOBULIN G or IMMUNOGLOBULIN M). The interaction of C1q and immunoglobulin activates the two proenzymes COMPLEMENT C1R and COMPLEMENT C1S, thus initiating the cascade of COMPLEMENT ACTIVATION via the CLASSICAL COMPLEMENT PATHWAY.
Inflammation of any part of the KIDNEY.
Abnormal responses to sunlight or artificial light due to extreme reactivity of light-absorbing molecules in tissues. It refers almost exclusively to skin photosensitivity, including sunburn, reactions due to repeated prolonged exposure in the absence of photosensitizing factors, and reactions requiring photosensitizing factors such as photosensitizing agents and certain diseases. With restricted reference to skin tissue, it does not include photosensitivity of the eye to light, as in photophobia or photosensitive epilepsy.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase.
Small RNAs found in the cytoplasm usually complexed with proteins in scRNPs (RIBONUCLEOPROTEINS, SMALL CYTOPLASMIC).
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
A tumor necrosis factor superfamily member that plays a role in the regulation of B-LYMPHOCYTE survival. It occurs as a membrane-bound protein that is cleaved to release an biologically active soluble form with specificity to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; B-CELL ACTIVATION FACTOR RECEPTOR; and B-CELL MATURATION ANTIGEN.
Acidic phospholipids composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol. They occur primarily in mitochondrial inner membranes and in bacterial plasma membranes. They are the main antigenic components of the Wassermann-type antigen that is used in nontreponemal SYPHILIS SERODIAGNOSIS.
Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that "collagen" was equivalent to "connective tissue", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term "collagen diseases" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494)
A syndrome with overlapping clinical features of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon. The disease is differentially characterized by high serum titers of antibodies to ribonuclease-sensitive extractable (saline soluble) nuclear antigen and a "speckled" epidermal nuclear staining pattern on direct immunofluorescence.
The smaller fragment formed when complement C4 is cleaved by COMPLEMENT C1S. It is an anaphylatoxin that causes symptoms of immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE) but its activity is weaker than that of COMPLEMENT C3A or COMPLEMENT C5A.
Inflammation of a serous membrane.
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
A form of cutaneous tuberculosis. It is seen predominantly in women and typically involves the NASAL MUCOSA; BUCCAL MUCOSA; and conjunctival mucosa.
Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.
Complexes of RNA-binding proteins with ribonucleic acids (RNA).
Highly conserved nuclear RNA-protein complexes that function in RNA processing in the nucleus, including pre-mRNA splicing and pre-mRNA 3'-end processing in the nucleoplasm, and pre-rRNA processing in the nucleolus (see RIBONUCLEOPROTEINS, SMALL NUCLEOLAR).
A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Abnormal immunoglobulins, especially IGG or IGM, that precipitate spontaneously when SERUM is cooled below 37 degrees Celsius. It is characteristic of CRYOGLOBULINEMIA.
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with IMMUNOGLOBULIN Gs. Three subclasses exist: Fc gamma RI (the CD64 antigen, a low affinity receptor), Fc gamma RII (the CD32 antigen, a high affinity receptor), and Fc gamma RIII (the CD16 antigen, a low affinity receptor).
Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
A PREDNISOLONE derivative with similar anti-inflammatory action.
A family of transcription factors that share an N-terminal HELIX-TURN-HELIX MOTIF and bind INTERFERON-inducible promoters to control GENE expression. IRF proteins bind specific DNA sequences such as interferon-stimulated response elements, interferon regulatory elements, and the interferon consensus sequence.
A classification of B-lymphocytes based on structurally or functionally different populations of cells.
A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.
The large fragment formed when COMPLEMENT C4 is cleaved by COMPLEMENT C1S. The membrane-bound C4b binds COMPLEMENT C2A, a SERINE PROTEASE, to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE).
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
A component of the CLASSICAL COMPLEMENT PATHWAY. C2 is cleaved by activated COMPLEMENT C1S into COMPLEMENT C2B and COMPLEMENT C2A. C2a, the COOH-terminal fragment containing a SERINE PROTEASE, combines with COMPLEMENT C4B to form C4b2a (CLASSICAL PATHWAY C3 CONVERTASE) and subsequent C4b2a3b (CLASSICAL PATHWAY C5 CONVERTASE).
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
Antibodies produced by a single clone of cells.
Inflammation of a transverse portion of the spinal cord characterized by acute or subacute segmental demyelination or necrosis. The condition may occur sporadically, follow an infection or vaccination, or present as a paraneoplastic syndrome (see also ENCEPHALOMYELITIS, ACUTE DISSEMINATED). Clinical manifestations include motor weakness, sensory loss, and incontinence. (Adams et al., Principles of Neurology, 6th ed, pp1242-6)
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue.
Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A member of tumor necrosis factor superfamily found on MACROPHAGES; DENDRITIC CELLS and T-LYMPHOCYTES. It occurs as transmembrane protein that can be cleaved to release a secreted form that specifically binds to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; and B CELL MATURATION ANTIGEN.
A subnormal level of BLOOD PLATELETS.
Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product.
The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.
Molecular sites on or in some B-lymphocytes and macrophages that recognize and combine with COMPLEMENT C3B. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids.
Individuals whose ancestral origins are in the continent of Europe.
Measurement of rate of settling of erythrocytes in anticoagulated blood.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION.
Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
A 206-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c (749-954), and C3dg (955-1303) in the presence COMPLEMENT FACTOR H.
Antibodies found in adult RHEUMATOID ARTHRITIS patients that are directed against GAMMA-CHAIN IMMUNOGLOBULINS.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
The genetic constitution of individuals with respect to one member of a pair of allelic genes, or sets of genes that are closely linked and tend to be inherited together such as those of the MAJOR HISTOCOMPATIBILITY COMPLEX.
Formation and development of a thrombus or blood clot in the blood vessel.
Enzymes that activate one or more COMPLEMENT PROTEINS in the complement system leading to the formation of the COMPLEMENT MEMBRANE ATTACK COMPLEX, an important response in host defense. They are enzymes in the various COMPLEMENT ACTIVATION pathways.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
A membrane-bound tumor necrosis family member that is expressed on activated antigen-presenting cells such as B-LYMPHOCYTES and MACROPHAGES. It signals T-LYMPHOCYTES by binding the OX40 RECEPTOR.
A signal transducer and activator of transcription that mediates cellular responses to INTERLEUKIN-12 in T-LYMPHOCYTES. Stat4 is an important signaling molecule for differentiation in TH1 CELLS.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases.
Antibodies obtained from a single clone of cells grown in mice or rats.
Pathological processes of the KIDNEY or its component tissues.
A pattern recognition receptor that binds several forms of imidazo-quinoline including the antiviral compound Imiquimod.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
Pathological conditions in the INTESTINES that are characterized by the gastrointestinal loss of serum proteins, including SERUM ALBUMIN; IMMUNOGLOBULINS; and at times LYMPHOCYTES. Severe condition can result in HYPOGAMMAGLOBULINEMIA or LYMPHOPENIA. Protein-losing enteropathies are associated with a number of diseases including INTESTINAL LYMPHANGIECTASIS; WHIPPLE'S DISEASE; and NEOPLASMS of the SMALL INTESTINE.
Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
Drugs that are used to treat RHEUMATOID ARTHRITIS.
A pattern recognition receptor that binds unmethylated CPG CLUSTERS. It mediates cellular responses to bacterial pathogens by distinguishing between self and bacterial DNA.
Individuals whose ancestral origins are in the southeastern and eastern areas of the Asian continent.
An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Mouse strains constructed to possess identical genotypes except for a difference at a single gene locus.
Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A loss of mucous substance of the mouth showing local excavation of the surface, resulting from the sloughing of inflammatory necrotic tissue. It is the result of a variety of causes, e.g., denture irritation, aphthous stomatitis (STOMATITIS, APHTHOUS); NOMA; necrotizing gingivitis (GINGIVITIS, NECROTIZING ULCERATIVE); TOOTHBRUSHING; and various irritants. (From Jablonski, Dictionary of Dentistry, 1992, p842)
A screening assay for circulating COMPLEMENT PROTEINS. Diluted SERUM samples are added to antibody-coated ERYTHROCYTES and the percentage of cell lysis is measured. The values are expressed by the so called CH50, in HEMOLYTIC COMPLEMENT units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
The age, developmental stage, or period of life at which a disease or the initial symptoms or manifestations of a disease appear in an individual.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Molecules on the surface of some B-lymphocytes and macrophages, that recognize and combine with the C3b, C3d, C1q, and C4b components of complement.
A subtype of non-receptor protein tyrosine phosphatases that is characterized by the presence of an N-terminal catalytic domain and a C-terminal PROLINE-rich domain. The phosphatase subtype is predominantly expressed in LYMPHOCYTES and plays a key role in the inhibition of downstream T-LYMPHOCYTE activation. Polymorphisms in the gene that encodes this phosphatase subtype are associated with a variety of AUTOIMMUNE DISEASES.
Substances that reduce or suppress INFLAMMATION.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES.
An HLA-DR antigen which is associated with HLA-DRB1 CHAINS encoded by DRB1*03 alleles.
Persons living in the United States having origins in any of the black groups of Africa.
Sites on an antigen that interact with specific antibodies.
Development of lesions in the lymph node characterized by infiltration of the cortex or paracortex by large collections of proliferating histiocytes and complete or, more often, incomplete necrosis of lymphoid tissue.
The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Fitzgerald factor (high molecular weight kininogen) clotting activity in human plasma in health and disease in various animal plasmas. (1/6365)

Fitzgerald factor (high molecular weight kininogen) is an agent in normal human plasma that corrects the impaired in vitro surface-mediated plasma reactions of blood coagulation, fibrinolysis, and kinin generation observed in Fitzgerald trait plasma. To assess the possible pathophysiologic role of Fitzgerald factor, its titer was measured by a functional clot-promoting assay. Mean +/- SD in 42 normal adults was 0.99+/-0.25 units/ml, one unit being the activity in 1 ml of normal pooled plasma. No difference in titer was noted between normal men and women, during pregnancy, or after physical exercise. Fitzgerald factor activity was significantly reduced in the plasmas of eight patients with advanced hepatic cirrhosis (0.40+/-0.09 units/ml) and of ten patients with disseminated intravascular coagulation (0.60+/-0.30 units/ml), but was normal in plasmas of patients with other congenital clotting factor deficiencies, nephrotic syndrome, rheumatoid arthritis, systemic lupus erythematosus, or sarcoidosis, or under treatment with warfarin. The plasmas of 21 mammalian species tested appeared to contain Fitzgerald factor activity, but those of two avian, two repitilian, and one amphibian species did not correct the coagulant defect in Fitzgerald trait plasmas.  (+info)

Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. (2/6365)

The fine specificity of the Ro and La proteins has been studied by several techniques. In general, there is agreement in a qualitative sense that autoantibodies bind multiple epitopes. For some specific antibody binding, different studies agree quantitatively, for instance, the binding of the carboxyl terminus of 60-kd Ro as described by 2 studies using different techniques and the presence of an epitope within the leucine zipper of 52-kd Ro. In addition, there is general agreement about the location of a prominent epitope at the RRM motif region of the La molecule. On the other hand, the many specific epitope regions of the molecules differ among these studies. These discrepancies are likely the result of using different techniques, sera, and peptide constructs as well as a result of inherent advantages and disadvantages in the individual approaches. Several theories concerning the origin of not only the antibodies, but also the diseases themselves, have been generated from studies of the fine specificity of antibody binding. These include a theory of a primordial foreign antigen for anti-Ro autoimmunity, molecular mimicry with regard to La and CCHB, as well as the association of anti-Ro with HLA. These remain unproven, but are of continuing interest. An explanation for the association of anti-60-kd Ro and anti-52-kd Ro in the sera of patients has sprung from evaluating antibody binding. Data demonstrating multiple epitopes are part of a large body of evidence that strongly suggests an antigen-driven immune response. This means that the autoantigens are directly implicated in initiating and sustaining autoimmunity in their associated diseases. A number of studies have investigated the possibility of differences in the immune response to these antigens in SS and SLE sera. While several differences have been reported, none have been reproduced in a second cohort of patients. Furthermore, none of the reported differences may be sufficiently robust for clinical purposes, such as distinguishing between SS with systemic features and mild SLE, although some might be promising. For instance, in at least 3 groups of SLE patients, no binding of residues spanning amino acids 21-41 of 60-kd Ro has been found. Meanwhile, 1 of those studies found that 41% of sera from patients with primary SS bound the 60-kd Ro peptide 21-41. Perhaps future studies will elaborate a clinical role of such a difference among SS and SLE patients. Study of the epitopes of these autoantigens has, in part, led to a new animal model of anti-Ro and anti-La. Non-autoimmune-prone animals are immunized with proteins or peptides that make up the Ro/La RNP. Such animals develop an autoimmune response to the entire particle, not just the immunogen. This response has been hypothesized to arise from autoreactive B cells. In another, older animal model of disease, the MRL-lpr/lpr mouse, B cells have recently been shown to be required for the generation of abnormal, autoreactive T cells. Thus, there are now powerful data indicating that B cells that produce autoantibodies are directly involved in the pathogenesis of disease above and beyond the formation of immune complexes. Given that the autoreactive B cell is potentially critical to the underlying pathogenesis of disease, then studying these cells will be crucial to further understanding the origin of diseases associated with Ro and La autoimmunity. Hopefully, an increased understanding will eventually lead to improved treatment of patients. Progress in the area of treatment will almost surely be incremental, and studies of the fine specificity of autoantibody binding will be a part of the body of basic knowledge contributing to ultimate advancement. In the future, the animal models will need to be examined with regard to immunology and immunochemistry as well as genetics. The development of these autoantibodies has not been studied extensively because upon presentation to medical care, virtually all patients have a full-  (+info)

Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. (3/6365)

OBJECTIVE: To determine any HLA associations with anti-beta2-glycoprotein I (anti-beta2GPI) antibodies in a large, retrospectively studied, multiethnic group of 262 patients with primary antiphospholipid antibody syndrome (APS), systemic lupus erythematosus (SLE), or another connective tissue disease. METHODS: Anti-beta2GPI antibodies were detected in sera using an enzyme-linked immunosorbent assay. HLA class II alleles (DRB1, DQA1, and DQB1) were determined by DNA oligotyping. RESULTS: The HLA-DQB1*0302 (DQ8) allele, typically carried on HLA-DR4 haplotypes, was associated with anti-beta2GPI when compared with both anti-beta2GPI-negative SLE patients and ethnically matched normal controls, especially in Mexican Americans and, to a lesser extent, in whites. Similarly, when ethnic groups were combined, HLA-DQB1*0302, as well as HLA-DQB1*03 alleles overall (DQB1*0301, *0302, and *0303), were strongly correlated with anti-beta2GPI antibodies. The HLA-DR6 (DR13) haplotype DRB1*1302; DQB1*0604/5 was also significantly increased, primarily in blacks. HLA-DR7 was not significantly increased in any of these 3 ethnic groups, and HLA-DR53 (DRB4*0101) was increased in Mexican Americans only. CONCLUSION: Certain HLA class II haplotypes genetically influence the expression of antibodies to beta2GPI, an important autoimmune response in the APS, but there are variations in HLA associations among different ethnic groups.  (+info)

Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. (4/6365)

OBJECTIVE: To study the in vitro effect of estrogen on IgG anti-double-stranded DNA (anti-dsDNA) antibody and total IgG production in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE), in order to elucidate its regulatory role in SLE. METHODS: PBMC from SLE patients and normal donors were cultured with 17beta-estradiol (E2). IgG anti-dsDNA antibodies, total IgG, and cytokine activity in the culture supernatants were measured by enzyme-linked immunosorbent assay. RESULTS: E2 enhanced production of IgG anti-dsDNA antibodies as well as total IgG in PBMC from SLE patients. Anti-dsDNA production in patients with inactive disease was less responsive to E2 than that in patients with active disease. E2 also enhanced total IgG, but not anti-dsDNA, production in the PBMC of normal donors. Antibody production was increased by E2 to a lesser extent in patients' B cells than in their PBMC. Anti-interleukin-10 (anti-IL-10) antibodies partially blocked the E2-induced increase in antibody production in patients' PBMC, but anti-IL-10 had no effect on B cells. E2 increased IL-10 production by patients' monocytes. Exogenous IL-10 acted additively with E2 in increasing antibody production in patients' B cells. CONCLUSION: These results suggest that E2 may polyclonally increase the production of IgG, including IgG anti-dsDNA, in SLE patients' PBMC by enhancing B cell activity and by promoting IL-10 production in monocytes. These findings support the involvement of E2 in the pathogenesis of SLE.  (+info)

Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. (5/6365)

OBJECTIVE: To determine rates of morbidity due to cardiovascular and cerebrovascular diseases among women with systemic lupus erythematosus (SLE). METHODS: I used the California Hospital Discharge Database, which contains information on all discharges from acute care hospitals in California, to identify women with SLE who had been hospitalized for treatment of either acute myocardial infarction (AMI), congestive heart failure (CHF), or cerebrovascular accident (CVA) from 1991 to 1994. I compared the proportions of hospitalizations for each cause among women with SLE with those in a group of women without SLE, for 3 age strata (18-44 years, 45-64 years, and > or =65 years). RESULTS: Compared with young women without SLE, young women with SLE were 2.27 times more likely to be hospitalized because of AMI (95% confidence interval [95% CI] 1.08-3.46), 3.80 times more likely to be hospitalized because of CHF (95% CI 2.41-5.19), and 2.05 times more likely to be hospitalized because of CVA (95% CI 1.17-2.93). Among middle-aged women with SLE, the frequencies of hospitalization for AMI and CVA did not differ from those of the comparison group, but the risk of hospitalization for CHF was higher (odds ratio [OR] 1.39, 95% CI 1.05-1.73). Among elderly women with SLE, the risk of hospitalization for AMI was significantly lower (OR 0.70, 95% CI 0.51-0.89), the risk of hospitalization for CHF was higher (OR 1.25, 95% CI 1.01-1.49), and the risk of hospitalization for CVA was not significantly different from those in the comparison group. CONCLUSION: Young women with SLE are at substantially increased risk of AMI, CHF, and CVA. The relative odds of these conditions decrease with age among women with SLE.  (+info)

Unilateral cataplexy associated with systemic lupus erythematosus. (6/6365)

A patient with systemic lupus erythematosus (SLE) developed attacks of unilateral cataplexy precipitated by laughter. Unilateral cataplexy has not been described previously in detail and its association with SLE is unique. The clinical details, investigations, and diagnostic criteria are discussed and a causal relationship between cataplexy and SLE is suggested.  (+info)

Autoreactive human T cell lines recognizing ribosomal protein L7. (7/6365)

Sera of patients suffering from systemic lupus erythematosus (SLE) frequently contain oligoclonal IgG autoantibodies with high affinity for the ribosomal protein L7 (rpL7). The humoral autoimmune response to rpL7 apparently is driven by antigen and T cell dependent. In order to analyze the T cell response to rpL7 we cultured peripheral blood lymphocytes of healthy individuals and SLE patients in the presence of recombinant rpL7. After 10 days, the cytokine response to re-stimulation with rpL7 was examined using a spot-ELISA. Measuring IFN-gamma secretion, the T cells of two patients and four healthy donors showed a significant increase in the number of spots as compared to control cells. Secretion of IL-4 or IL-10 was not detected. From the antigen-stimulated primary cultures we established by limiting dilution cloning six rpL7-reactive, IFN-gamma-secreting T cell lines which show a CD3+CD4+CD8- phenotype. One line additionally was shown to be positive for HLA-DR and CD45R0, but negative for CD27 and CD31. The cell lines carry alphabeta TCR chains which differ from each other in sequence and specificity. rpL7 fragments rich in basic amino acids could be identified as epitopes recognized by the TCR of three cell lines. Recognition of rpL7 is HLA-DR6 restricted or respectively HLA-DP restricted in the two cell lines analyzed.  (+info)

Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. (8/6365)

Systemic lupus erythematosus (SLE) is the prototype of human autoimmune diseases. Its genetic component has been suggested by familial aggregation (lambdas = 20) and twin studies. We have screened the human genome to localize genetic intervals that may contain lupus susceptibility loci in a sample of 188 lupus patients belonging to 80 lupus families with two or more affected relatives per family using the ABI Prism linkage mapping set which includes 350 polymorphic markers with an average spacing of 12 cM. Non-parametric multipoint linkage analysis suggests evidence for predisposing loci on chromosomes 1 and 18. However, no single locus with overwhelming evidence for linkage was found, suggesting that there are no 'major' susceptibility genes segregating in families with SLE, and that the genetic etiology is more likely to result from the action of several genes of moderate effect. Furthermore, the support for a gene in the 1q44 region as well as in the 1p36 region is clearly found only in the Mexican American families with SLE but not in families of Caucasian ethnicity, suggesting that consideration of each ethnic group separately is crucial.  (+info)

TY - JOUR. T1 - Flares in pediatric systemic lupus erythematosus. AU - Weiss, Jennifer E.. AU - Sison, Cristina P.. AU - Ilowite, Norman T.. AU - Gottlieb, Beth S.. AU - Eberhard, Barbara A.. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Objective. To determine the flare rate and the change in Safety of Estrogens in Lupus Erythematosus: National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA SLEDAI) score with disease flare in pediatric systemic lupus erythematosus (pSLE). Methods. A retrospective chart review of 62 patients with pSLE (ages 5-20 yrs). A flare was defined as the start of, or increase in, the dose of corticosteroids and/or the addition of an immunosuppressive medication. All pre-flare, flare, and post-flare visits were recorded with a SELENA SLEDAI score calculated for each visit. The flare rate was calculated by dividing the total number of flares in the cohort by the total followup years. Results. Sixty-two patients were eligible. Forty-seven patients had 112 ...
OBJECTIVE: To describe the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), a modification of SLEDAI to reflect persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences, and to validate SLEDAI-2K against the original SLEDAI as a predictor for mortality and as a measure of global disease activity in the clinic. METHODS: All visits in our cohort of 960 patients were used to correlate SLEDAI-2K against the original SLEDAI, and the whole cohort was used to validate SLEDAI-2K as a predictor of mortality. A subgroup of 212 patients with SLE followed at the Lupus Clinic who had 5 regular visits, 3-6 months apart, in 1991-93 was also included. An uninvolved clinician evaluated each patient record and assigned a clinical activity level. The SLEDAI score was calculated from the database according to both the original and modified definitions. RESULTS: SLEDAI-2K correlated highly (r = 0.97) with SLEDAI. Both methods for SLEDAI ...
Patients with the autoimmune disease systemic lupus erythematosus (SLE) develop pathogenic antibodies against their own self-antigens. U1-70(131-150):I-Ek (without phosphorylation) correlates with disease intensity and antiCU1-70 autoantibody creation. These T cells express RORt and produce IL-17A also. Furthermore, the U1-70Cparticular Compact disc4+ T cells that generate IL-17A are discovered within a subset of sufferers Dovitinib with SLE and so are significantly elevated in sufferers with blended connective tissues disease. These scholarly research offer equipment for learning antigen-specific POLDS Compact disc4+ T cells in lupus, and show an Dovitinib antigen-specific way to obtain IL-17A in autoimmune disease. Systemic lupus erythematosus (SLE) can be an autoimmune disease where sufferers develop high-titer, specific highly, isotype-switched autoantibodies against DNA- and RNA- filled with autoantigens (1). U1-70, U1-A, and U1-C, with U1-RNA as well as the seven Smith proteins jointly, ...
OBJECTIVES: To perform systematic assessment of ovarian reserve markers using a combination of tests in juvenile systemic lupus erythematosus (JSLE) patients without amenorrhoea. METHODS: Twenty-seven consecutive JSLE female patients and 13 healthy c
Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies ≥1:80 and/or anti-double-stranded DNA antibodies ≥30 IU/ml) at baseline was retrospectively evaluated using the SRI. ...
Clinical trial for SYSTEMIC LUPUS ERYTHEMATOSUS , Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
LU, Zhimin et al. Altered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infections. Braz J Med Biol Res [online]. 2019, vol.52, n.4, e8131. Epub 15-Abr-2019. ISSN 1414-431X. https://doi.org/10.1590/1414-431x20198131.. The leading cause of death in systemic lupus erythematosus (SLE) patients is infection. The objective of this study was to evaluate the distribution of lymphocyte subsets in untreated SLE patients with infections. This was a cross-sectional study. Data from January 2017 to May 2018 were collected. Flow cytometry was used to measure the peripheral lymphocyte subsets including CD3+T cells, CD4+T cells, CD8+T cells, CD19+B cells, CD3-CD16+CD56NK cells, and CD3+CD16+CD56NKT cells in 25 healthy controls and 52 treatment-naive SLE patients, among whom 13 were complicated with infections. Association between the lymphocyte subsets and infections was further analyzed. SLE patients with infections (n=13) showed a significantly higher incidence rate of ...
OBJECTIVE: To determine the impact of the patients sex on the manifestations and outcome of systemic lupus erythematosus (SLE).. METHODS: We studied SLE patients who were ages 16 years or older and had a disease duration of , or =5 years at the time of enrollment in the LUpus in MInorities, NAture versus nurture cohort, a multiethnic cohort consisting of Hispanic, African American, and Caucasian patients. Socioeconomic/demographic, clinical, and serologic features, as well as disease activity (by the Systemic Lupus Activity Measure, Revised) and damage accrual (by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index) were compared between male and female patient groups. Multivariable analyses using male sex and damage accrual as dependent variables were then performed.. RESULTS: Sixty-three male SLE patients (10.2%) from all ethnic groups were included. The mean ages of the male and female patients were comparable. Factors that were either more ...
TY - JOUR. T1 - Possible triggering effect of cytomegalovirus infection on systemic lupus erythematosus. AU - Nawata, M.. AU - Seta, N.. AU - Yamada, M.. AU - Sekigawa, I.. AU - Iida, N.. AU - Hashimoto, H.. PY - 2001. Y1 - 2001. N2 - We report on a patient with systemic lupus erythematosus (SLE) who showed elevated titers of IgM antibodies to cytomegalovirus (CMV), suggesting CMV infection at the onset of SLE. Serum CMV antigens were also detected in the patient. These findings raise the possibility that CMV infection may be related to the onset of SLE in certain patients.. AB - We report on a patient with systemic lupus erythematosus (SLE) who showed elevated titers of IgM antibodies to cytomegalovirus (CMV), suggesting CMV infection at the onset of SLE. Serum CMV antigens were also detected in the patient. These findings raise the possibility that CMV infection may be related to the onset of SLE in certain patients.. KW - Cytomegalovirus. KW - Proteinuria. KW - Systemic lupus ...
Immunoglobulin M (IgM) autoreactivity to malondialdehyde (MDA) protein modifications is part of the natural antibody repertoire in health and may have beneficial functions. In contrast, IgG anti-MDA are increased in chronic inflammation and autoimmunity and may instead have pathogenic properties. Herein, we investigated serum IgG anti-MDA levels by enzyme-linked immunosorbent assay (ELISA) in 398 systemic lupus erythematosus (SLE) patients in the Swedish Karolinska SLE cohort and compared these to findings in 225 US SLE patients from New York University and Johns Hopkins University. In two independent cohorts, IgG anti-MDA levels correlated positively with disease activity by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; p | 0.0001, Spearman R = 0.3). Meta-analysis found an odds ratio of 2.7 (confidence interval (CI) 1.9-3.9; p | 0.0001) for high anti-MDA IgG levels with active disease (SLEDAI ≥ 6). Furthermore, IgG anti-MDA correlated directly with erythrocyte sedimentation rate
An SRI response is defined as a reduction from baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) score of at least 4 points, no worsening in Physicians Global Assessment (PhGA) (with worsening defined as an increase in PhGA of more than 0.30 point from baseline), no British Isles Lupus Assessment Group A (BILAG A) organ domain score, and no more than 1 new BILAG B organ domain score from baseline ...
Systemic lupus erythematosus: Find the most comprehensive real-world symptom and treatment data on systemic lupus erythematosus at PatientsLikeMe. 37842 patients with systemic lupus erythematosus experience muscle pain, joint swelling, skin sensitivity to sun (photosensitivity), joint pain, and chest pain and use Hydroxychloroquine, Prednisone, Methotrexate, Belimumab, and Azathioprine to treat their systemic lupus erythematosus and its symptoms.
Both systemic lupus erythematosus (SLE) and its treatment can cause immunosuppression and a decreased response to vaccination. We evaluated 30 children and adolescents with SLE, and 14 age-matched healthy subjects (control group) regarding immunophenotyping and lymphocyte apoptosis by flow cytometry …
TY - JOUR. T1 - Delineation of the human systemic lupus erythematosus anti-Smith antibody response using phage-display combinatorial libraries. AU - Del Rincon, I.. AU - Zeidel, M.. AU - Rey, E.. AU - Harley, J. B.. AU - James, J. A.. AU - Fischbach, M.. AU - Sanz, I.. PY - 2000/12/15. Y1 - 2000/12/15. N2 - The anti-Smith (Sm) autoantibody response is highly specific for systemic lupus erythematosus and is predominantly targeted to the Sm-B/B and -D1 polypeptides. In all animal species thus far studied, anti-Sm Abs initially recognize proline-rich epitopes in the carboxyl terminus of the Sm-B/B protein and subsequently to multiple other epitopes in B/B and D. The absence of appropriate mAbs has limited our understanding of the genetic and structural basis of this autoimmune response. Using phage-display technology and lymphocytes from a systemic lupus erythematosus patient we have generated the first and only panel of human IgG anti-Sm mAbs thus far available. These Abs reproduced to a ...
Results The serum levels of sCXCL16 in jSLE patients were higher than controls (p,0.001), they were also siginificantly higher in patients with alopecia or malar rash than other jSLE .Positive correlation was identified between serum levels of sCXCL16 and SLEDAI score. There was a significant positive correlation between sCXCL16 levels and severity of lupus nephritis as assessed by renal biopsy. Serum levels of sCXCL16 were positively significantly correlated with the 24 hour urine protein,ANA, SBP, DBP AND ESR 1st hour. Serum sCXCL16 level was significanly negatively correlated with C3 serum level. ...
Global Glucocorticoid for Systemic Lupus Erythematosus Status and Trend Report offers a comprehensive analysis of Glucocorticoid for Systemic Lupus Erythematosus industry, standing on the readers perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.. The Asia-Pacific will occupy more market share in the following years, especially in China, also fast growing India and Southeast Asia regions. North America, especially The United States, will still play an important role which cannot be ignored. Any changes from the United States might affect the development trend of Glucocorticoid for Systemic Lupus Erythematosus. Europe also plays important roles in the global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%. This report studies the Glucocorticoid for Systemic Lupus Erythematosus market status and ...
View more ,Periodontal disease is a group of chronic inflammatory diseases affecting tooth-supporting tissues. The early stage is the presence of biofilm-associated gingival inflammation which, in patients having juvenile systemic lupus erythematosus (SLE), might function as a reservoir of anaerobic Gram-negative bacteria such as Porphyromonas gingivalis. Porphyromonas gingivalis has been associated with an increased level of anticardiolipin and anti-b2-glycoprotein antibodies in patients with SLE, which implies periodontal disease as a modifiable risk factor for SLE morbility1 . Besides, Porphyromonas gingivalis also express functional endogenous Peptidylarginine deiminase (PAD) enzymes, which catalyzes a citrullination reaction that can lead to formation of citrullinated peptides. PAD can frequently be recognized in sera of patients with rheumatoid arthritis, systemic lupus erythematosusand primary Sjögren syndrome2 . Laugisch et al. 3 reported that PAD secreted by Porphyromonas gingivalis ...
Autoantibodies against complement C1q (anti-C1q Abs) were shown to strongly correlate with the occurrence of severe nephritis in patients with systemic lupus erythematosus (SLE), suggesting a potential pathogenic role by interfering with the complement cascade. To analyze the humoral immune response against C1q at the molecular level, we screened a bone marrow-derived IgGkappa/IgGlambda Fab phage display library from a SLE patient with high anti-C1q Ab titer against purified human C1q. Six Fabs that exhibited strong binding to C1q in ELISA were isolated. The anti-C1q Fabs recognized neoepitopes that were only exposed on bound C1q and not present on soluble C1q mapping to different regions of the collagen-like region of C1q. Analysis of the genes encoding the variable H and L chains of the IgG-derived anti-C1q Fab revealed that all the variable H and L chain regions were highly mutated, with nucleotide and amino acid homologies to the closest germline in the range of 71-97% (average 85 +/- 4) and ...
TY - JOUR. T1 - Cardiac pathology of systemic lupus erythematosus. AU - Jain, D.. AU - Halushka, Marc K. PY - 2009/7. Y1 - 2009/7. N2 - Systemic lupus erythematosus is a common chronic autoimmune disorder causing injury to many organ systems. Cardiac complications of lupus affect most parts of the heart. These include pericarditis, myocarditis, endocarditis and coronary artery disease. While many histopathological findings in lupus-related cardiac diseases are non-specific, there are a few important findings which pathologists should be aware of. This review provides pathological descriptions of these entities.. AB - Systemic lupus erythematosus is a common chronic autoimmune disorder causing injury to many organ systems. Cardiac complications of lupus affect most parts of the heart. These include pericarditis, myocarditis, endocarditis and coronary artery disease. While many histopathological findings in lupus-related cardiac diseases are non-specific, there are a few important findings which ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Results The mean age of the JSLE children was 13.25±2.09 years and 23.17±4.26 years for JO-SLE cases. JO-SLE cases were older at disease onset with a higher female-to-male ratio. There were no noticeable gender differences. There was a significantly higher frequency of serositis, nephritis and hematological involvement in the JO-SLE (57.7%, 76.9% and 73.1%) compared to the JSLE cases (15.4%; 30.8% and 30.8%) (p,0.001 for all). The erythrocyte sedimentation rate, creatinine and proteinuria were significantly increased in JO-SLE while alkaline phosphatase was higher in JSLE cases. In JO-SLE cases, SLEDAI significantly increased (5.96±6.18 vs 3.12±1.97; p=0.003) and the SLICC tended to increase compared to the JSLE children. More JO-SLE cases received hydroxychloroquine and azathioprine. ...
Fanouriakis A, Kostopoulou M, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun;78(6):736-745. Systemic lupus erythematosus (lupus). National Institute of Arthritis and Musculoskeletal and Skin Diseases website. Available at: http://www.niams.nih.gov/Health%5FInfo/Lupus/default.asp. Accessed January 8, 2021. Systemic lupus erythematosus (SLE). EBSCO DynaMed website. Available at: https://www.dynamed.com/condition/systemic-lupus-erythematosus-sle. Accessed January 8, 2021. Understanding lupus. Lupus Foundation of America website. Available at: http://www.lupus.org/answers/topic/understanding-lupus. Accessed January 8, 2021. ...
Amital H, Szekanecz Z, Szücs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010 Jun;69(6):1155-7. (Epub ahead of print). Bast A, Haenen GR. Lipoic acid: a multifunctional antioxidant. Biofactors. 2003;17(1-4):207-13.. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Nov;46(11):2924-7.. Costenbader KH, Kang JH, Karlson EW. Antioxidant Intake and Risks of Rheumatoid Arthritis and Systemic Lupus Erythematosus in Women. Am J Epidemiol. 2010 Jun 9. [Epub ahead of print]. Dryden GW Jr, Deaciuc I, Arteel G, McClain CJ. Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep. 2005;7(4):308-16.. El-Badri NS, Hakki A, Ferrari ...
Is melasma a symptom of systemic lupus erythematosus sle - Is there a cure for systemic lupus erythematosus (sle)? SLE treatment. Systemic lupus erythematosus (sle) is a long-term autoimmune disorder that may affect the skin, joints, kidneys, brain, and other organs. There is no cure for sle. The goal of treatment is to control symptoms.
Arntfield RT, Hicks CM. Systemic lupus erythematosus and the vasculitides. In: Walls RM, Hockberger RS, Gausche-Hill M, eds. Rosens Emergency Medicine: Concepts and Clinical Practice. 9th ed. Philadelphia, PA: Elsevier; 2018:chap 108.. Crow MK. Etiology and pathogenesis of systemic lupus erythematosus. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, ODell JR, eds. Kelley and Firesteins Textbook of Rheumatology. 10th ed. Philadelphia, PA: Elsevier; 2017:chap 79.. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6) :736-745. PMID: 30926722 pubmed.ncbi.nlm.nih.gov/30926722/.. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808. PMID: 22556106 pubmed.ncbi.nlm.nih.gov/22556106/.. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target ...
Systemic lupus erythematosus (SLE) is a rheumatic disease characterized by autoantibodies directed against self-antigens, immune complex formation, and immune dysregulation, resulting in damage to essentially any organ. The disease can affect, for example, the kidneys, skin, blood cells, and nervous system.
Table of Contents. Table of Contents 2. List of Tables 7. List of Figures 9. Introduction 10. Global Markets Direct Report Coverage 10. Systemic Lupus Erythematosus Overview 11. Therapeutics Development 12. Pipeline Products for Systemic Lupus Erythematosus-Overview 12. Pipeline Products for Systemic Lupus Erythematosus-Comparative Analysis 13. Systemic Lupus Erythematosus-Therapeutics under Development by Companies 14. Systemic Lupus Erythematosus-Therapeutics under Investigation by Universities/Institutes 19. Systemic Lupus Erythematosus-Pipeline Products Glance 20. Late Stage Products 20. Clinical Stage Products 21. Early Stage Products 22. Unknown Stage Products 23. Systemic Lupus Erythematosus-Products under Development by Companies 24. Systemic Lupus Erythematosus-Products under Investigation by Universities/Institutes 29. Systemic Lupus Erythematosus-Companies Involved in Therapeutics Development 30. 4SC AG 30. AbbVie Inc. 31. Ablynx NV 32. Actelion Ltd 33. AiCuris GmbH & Co. KG 34. Amgen ...
TY - JOUR. T1 - Echocardiographic observation of acute myocarditis with systemic lupus erythematosus. AU - Ueda, Takashi. AU - Mizushige, Katsufumi. AU - Aoyama, Tohru. AU - Tokuda, Michiaki. AU - Kiyomoto, Hideyasu. AU - Matsuo, Hirohide. PY - 2000/2/1. Y1 - 2000/2/1. N2 - Although myocarditis from a series of autopsies of patients with systemic lupus erythematosus was frequently observed, the incidence of clinically apparent myocardial dysfunction was low. A 30-year-old woman with systemic lupus erythematosus was examined by echocardiography. An acoustic densitometry was followed at the left ventricular posterior wall throughout the clinical course. A decrease in the magnitude of cyclic variation of integrated backscatter (IB) was observed before treatment. Following the combined treatment, steroid and cyclophosphamide, a repeated ultrasonic tissue characterization showed an increase in the magnitude of cyclic variation of IB. It is thought that ultrasonic tissue characterization may be a ...
Systemic lupus erythematosus Bluish complexion, Bluish skin, Blue-tinge to the skin, Cough with cloudy, fishy-smelling mucus, Cough with cloudy, fishy-smelling sputum, , Chronic constipation (elderly people), , systemic lupus erythematosus
Get information, facts, and pictures about Systemic Lupus Erythematosus at Encyclopedia.com. Make research projects and school reports about Systemic Lupus Erythematosus easy with credible articles from our FREE, online encyclopedia and dictionary.
The purpose of the present study was to compare dynamic muscle strength, functional performance, fatigue, and quality of life in premenopausal systemic lupus erythematosus (SLE) patients with low disease activity versus matched-healthy controls and to determine the association of dynamic muscle strength with fatigue, functional performance, and quality of life in SLE patients. We evaluated premenopausal (18-45 years) SLE patients with low disease activity (Systemic lupus erythematosus disease activity index [SLEDAI]: mean 1.5 ± 1.2). The control (n = 25) and patient (n = 25) groups were matched by age, physical characteristics, and the level of physical activities in daily life (International Physical Activity Questionnaire IPAQ). Both groups had not participated in regular exercise programs for at least six months prior to the study. Dynamic muscle strength was assessed by one-repetition maximum (1-RM) tests. Functional performance was assessed by the Timed Up and Go (TUG), in 30-s test a chair stand
To explore the inadequacies of health service and its impact on clinical outcomes of patients with systemic lupus erythematosus (SLE) in China. A total of 210 SLE patients were randomly recruited between January 2017 and January 2018. Each patient received self-report questionnaires to assess medication adherence [Compliance Questionnaire for Rheumatology (CQR)], beliefs about medicines [Beliefs about Medicines Questionnaire (BMQ)] and satisfaction about medicine information [the Satisfaction with Information about Medicines Scale (SIMS)]. Associations between SLE disease activity index (SLEDAI-2 K) and observed factors were analyzed by multiple logistic regression. Based on CQR, only 28.10% patients were adherent. The score of BMQ was 2.85 ± 5.42, and merely 32.38% patients were satisfied with the information about their prescribed medicines. Disease activity was associated with SIMS, EuroQol five-dimensions [EQ5D], Systemic Lupus International Collaborating Clinics (SLICC), depression, use of NSAID
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that significantly affects health-related quality of life (HRQOL): physical, psychologic, mental, and social aspects of well-being that are influenced by disease, in the context of life experiences and expectations specific to each patient1. A relapsing, remitting chronic disease, SLE results in disability in 20%-40% of afflicted young and middle-aged women and men2. In patients with SLE, HRQOL is influenced by disease activity and symptoms of fatigue, depression, pain, sleep disturbances, and cognitive dysfunction3. Across 5 randomized controlled trials (RCT) in SLE, baseline HRQOL scores were low and were similar to those of subjects following myocardial infarction or with chronic congestive heart failure4. Lower scores were highly correlated with history of renal disease, presence of anti-dsDNA antibodies, higher disease activity scores by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and/or Safety of ...
Group A only: patients on immunosuppressive treatments had them withdrawn at baseline. All patients were allowed up to 160 mg depomedrol at baseline which could be repeated within two weeks up to a total of 4 shots maximum or until satisfactory improvement. Time to flare was calculated from baseline. moderate disease at baseline was defined as up to 3 BILAG B (moderate disease) organ scores, no BILAG A (severe disease) score and a SLEDAI ,/= 10. Severe disease required ,3 BILAG B, OR at least one BILAG A OR SLEDAI , 10 or meeting criteria for a severe flare on the SELENA SLEDAI flare index. At baseline 25 patients with moderate disease. 16 patients had severe disease. Note: severe rash with A on BILAG is only SLEDAI=2, explaining some discrepancies in measures ...
Keywords: Panretinal photocoagulation Retinal vascular occlusion Systemic lupus erythematosus Intro Systemic lupus erythematosus can be a multisystem disease of unfamiliar etiology seen as a several autoimmune phenomena with lesions in multiple body organ systems. Ocular manifestations of systemic BML-275 lupus erythematosus (SLE) consist of mucocutaneous involvement from the eyelids supplementary Sjogrens symptoms optic neuropathy. The retinopathy includes cotton wool spots with or without retinal hemorrhages generally.1-3 Vaso-occlusive disease particularly in the current presence of antiphospholipid antibodies usually trigger devastating and long term damage to visible function regardless of strenuous treatment and requires treatment with anticoagulation and proliferative retinopathy is treated with laser beam therapy.2 3 Case record A 35-year-old female was admitted due to sudden loss of visual acuity in the still left attention. She have been diagnosed as experiencing systemic lupus ...
Introduction: Patients with systemic lupus erythematosus (SLE) are at increased risk of metabolic syndrome (MetS) and its complications. In absence of..
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic, autoimmune disease. Genome-wide association studies (GWAS) have identified multiple risk SNPs in HLA and non-HLA gene regions. There is evidence that genetics are also important in lupus nephritis (LN) risk. LN is one of the most common and severe manifestations of SLE. The purpose of this study was to determine the association of known SLE risk SNPs with LN in both childhood-onset (cSLE) and adult-onset SLE (aSLE) populations. Methods: The study population included two tertiary care SLE cohorts; one with cSLE and the other with aSLE. Participants met American College of Rheumatology (ACR) and/or Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE, with prospectively collected clinical and laboratory data. Participants were genotyped on the Illumina MEGA or Omni1 arrays. Principal components were calculated in reference to the 1000 genomes project, and ancestry was genetically ...
This paper will explore juvenile Systemic Lupus Erythematosus. It will also explore its signs, symptoms, diagnosis, prognosis, statistics, treatment, complications, risk factors, and diet.
Objective(s): Apoptosis is a tightly regulated process and plays a crucial role in autoimmune diseases. Because abnormalities in apoptosis are considered to be involved in the pathogenesis of systemic lupus erythematosus (SLE), in present study we studied the apoptosis in T lymphocytes from Iranian SLE patientsat protein and gene expression levels for some molecules which are involved in apoptosis pathways. Materials and Methods: Thirty five SLE patients (23 female, 12 male), and 20 age matched controls (10 female, 10 male) participated in this study. T lymphocytes were isolated from peripheral blood mononuclear cells (PBMCs) using MACS method. Apoptosis rate was studied at protein level by flow cytometer using Annexin V, and at gene expression level using semi-quantitative RT-PCR method for detection of Fas, FasL, Bcl-2, caspase 8, and caspase 9 genes. Results: The percentage of apoptotic cells in SLE patients was not different in comparison with controls (20.2% ± 1.4 vs 21.1% ± 1.0), but the
TY - JOUR. T1 - Genetic ancestry, serum interferon- αactivity, and autoantibodies in systemic lupus erythematosus. AU - Ko, Kichul. AU - Franek, Beverly S.. AU - Marion, Miranda. AU - Kaufman, Kenneth M.. AU - Langefeld, Carl D.. AU - Harley, John B.. AU - Niewold, Timothy B.. PY - 2012/6. Y1 - 2012/6. N2 - Objective. To investigate and refine the relationships among systemic lupus erythematosus (SLE) and related autoantibodies, interferon-α (IFN-α), and various ancestral backgrounds. Methods. We investigated quantitatively defined genetic ancestry through principal component analysis in place of self-reported ancestry. Results. African ancestry was found to be associated with presence of anti-RNP antibody (p = 0.0026), and anti-RNP was correlated with high levels of IFN-α (p = 2.8 × 10 -5). Conclusion. Our data support a model in which African ancestry increases the likelihood of SLE-associated autoantibody formation, which subsequently results in higher levels of serum IFN-α. The Journal ...
Data abstracted retrospectively from the charts at 11,359 clinic visits for 310 patients with SLE to the Montreal General Hospital were used to investigate the associations of recent corticosteroid dose and recent Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with 8 CHD risk factors (total serum cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein cholesterol, apolipoprotein B [Apo B], triglycerides, systolic blood pressure [BP], body mass index, and blood glucose) and the aggregate estimate of 2-year CHD risk. Separate multivariable linear regression models estimated the mutually-adjusted effects of average daily corticosteroid dose and average SLEDAI score within the past year on the current level of each risk factor while adjusting for age, sex, cumulative damage score, disease duration, and, where appropriate, use of relevant medications ...
Introduction Systemic Lupus Erythematosus (SLE) shows a spectrum of clinical manifestations that complicate its diagnosis, treatment and research. This variability is likely related with environmental exposures and genetic factors among which known SLE susceptibility loci are prime candidates. The first published analyses seem to indicate that this is the case for some of them, but results are still inconclusive and we aimed to further explore this question. Methods European SLE patients, 1444, recruited at 17 centres from 10 countries were analyzed. Genotypes for 26 SLE associated SNPs were compared between patients with and without each of 11 clinical features: ten of the American College of Rheumatology (ACR) classification criteria (except ANAs) and age of disease onset. These analyses were adjusted for centre of recruitment, top ancestry informative markers, gender and time of follow-up. Overlap of samples with previous studies was excluded for assessing replication. Results There were three
The Janssen Pharmaceutical Companies of Johnson & Johnson presented this week results of two analyses from a Phase 2 study of Stelara®*(ustekinumab) in systemic lupus erythematosus (SLE). The studies highlight not only the sustained clinical benefit of ustekinumab - an anti-interleukin (IL) IL-12/23 p40 neutralising monoclonal antibody - on SLE disease activity at one-year, but also show a reduction in the rate of severe flares.. They also provide new insights into the possible pathway through which ustekinumab is acting in SLE patients who respond to IL-12/23 p40 blockade.1,2. The Phase 2 study, presented by lead study investigator Ronald van Vollenhoven MD PhD and colleagues, is a global randomized, placebo-controlled trial in 102 adults with seropositive SLE by Systemic Lupus International Collaborating Clinics (SLICC) criteria and active disease despite ongoing standard of care therapy (steroid, antimalarial and/or immunosuppressive therapies).1Patients were randomized (3:2) to receive ...
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by production of autoantibodies and immune complex deposition in various organs. Aberrations in the T lymphocyte compartment and dysregulated cytokine production are key features of SLE pathogenesis and disease progression. Recently, the role of the interleukin (IL)-17/IL-23 axis in the pathogenesis of SLE has been reported. IL-23 and IL-23R are essential for expansion of pathogenic IL-17-producing T lymphocytes and have been shown to be important in the pathogenesis of lupus in animal models. In this study, the expression of IL-23R and IL-17 in CD4+ and CD8+ T lymphocytes in peripheral blood mononuclear cells (PBMCs) of SLE patients and control subjects were examined by flow cytometry. Twenty-nine SLE patients and 10 control subjects were recruited in this study. Patients were divided into active and inactive groups based on the SLE disease activity index (SLEDAI). As another disease control population, five psoriatic patients
The National Institute of Allergy and Infectious Diseases has awarded a grant to Progentec to fast-track research into new tests for measuring systemic lupus erythematosus disease activity.
INTRODUCTION: Pulmonary arterial hypertension is a complication of systemic lupus erythematosus. Mortality in pregnant patients with pulmonary arterial hypertension related to connective tissue disease is as high as 56%. The authors report the first case of a successful maternal-fetal outcome in a pregnant patient with systemic lupus erythematosus-associated pulmonary arterial hypertension treated with sildenafil and inhaled iloprost during pregnancy and until several weeks after caesarean section. CASE PRESENTATION: The case presented is of a 29-year-old woman with systemic lupus erythematosus and associated severe pulmonary arterial hypertension. Vasodilator therapy with bosentan and sildenafil, immunosuppressive therapy with prednisone, hydroxychloroquine and azathioprine and oral anticoagulation (phenprocoumon) had normalized her right ventricular over right atrial pressure when she was diagnosed in her 5th week of pregnancy. The teratogenic drugs bosentan and phenprocoumon were stopped, the ...
The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 Classification Criteria for systemic lupus erythematosus (SLE) have been validated with high sensitivity and specificity. We evaluated the performance of the new criteria with regard to disease duration, sex and race/ethnicity, and compared its performance against the Systemic Lupus International Collaborating Clinics (SLICC) 2012 and ACR 1982/1997 criteria.Twenty-one SLE centres from 16 countries submitted SLE cases and mimicking controls to form the validation cohort. The sensitivity and specificity of the EULAR/ACR 2019, SLICC 2012 and ACR 1982/1997 criteria were evaluated.The cohort consisted of female (n=1098), male (n=172), Asian (n=118), black (n=68), Hispanic (n=124) and white (n=941) patients; with an SLE duration of 1 to ,3 years (n=196) and ≥5 years (n=879). Among patients with 1 to ,3 years disease duration, the EULAR/ACR criteria had better sensitivity than the ACR criteria (97% vs 81%). The ...
Introduction: Neuropsychiatric systemic lupus erythematosus is often clinically challenging to diagnose, treat and monitor. Although brain magnetic resonance imaging is frequently performed before lumbar puncture in neuropsychiatric systemic lupus erythematosus, it is not clear from the literature whether specific brain magnetic resonance imaging findings are associated with distinct clinical features of neuropsychiatric systemic lupus erythematosus. Methods: We conducted a systematic review and meta-analysis on published studies of neuropsychiatric systemic lupus erythematosus including brain magnetic resonance imaging and the 1999 American College of Rheumatology-defined clinical neuropsychiatric systemic lupus erythematosus syndromes to determine their relationship. Pooled prevalence and risk ratio for distinct neuropsychiatric systemic lupus erythematosus associations were determined with 95% confidence intervals. Results: Of 821 studies screened, 21 fulfilled inclusion criteria. A total of ...
Neuropsychiatric systemic lupus erythematosus (NP-SLE) is one of the major cause of morbidity in systemic lupus erythematosus patients and its treatment depends on identification of pathogenic mechanisms. We describe the rare case of neuropsychiatric systemic lupus erythematosus (NP-SLE) complicated by pericardial effusion combined to low C4 level persisting and hyperprolactinaemia. A cyclophosphamide therapy showed a good response in a 21-year old woman with disturbances in thought processes and an acute confusional state with sierositis. This paper confirms that a cyclophosphamide therapy contributes to control a disease activity by a mechanism of prolactin level reduction. Other studies occur to evaluate this hypothesis.
Signs of Bullous systemic lupus erythematosus including medical signs and symptoms of Bullous systemic lupus erythematosus, symptoms, misdiagnosis, tests, common medical issues, duration, and the correct diagnosis for Bullous systemic lupus erythematosus signs or Bullous systemic lupus erythematosus symptoms.
A family is reported in which two siblings had congenital complete heart block with resultant congestive heart failure, the father and paternal grandfather show adult-onset conduction defects, and the mother has systemic lupus erythematosis. The interaction of heredity and environment is discussed in this context. A review of the literature on familial complete heart block suggests that so-called pure congenital-onset familial heart block, originally felt to be genetic, may in fact have an important enivronmental component, specifically related to ongoing maternal factors such as systemic lupus erythematosis. ...
TY - JOUR. T1 - Effect of plasmapheresis on T and B lymphocyte functions in patients with systemic lupus erythematosus. T2 - A double blind study. AU - Tsokos, G. C.. AU - Balow, J. E.. AU - Huston, David P.. AU - Wei, N.. AU - Decker, J. L.. PY - 1982/7/13. Y1 - 1982/7/13. N2 - Nine patients with active systemic lupus erythematosus entered a double-blind randomized trial to study the therapeutic effect of vigorous versus sham reinfusion plasmapheresis. Four of them received real plasmapheresis while five received sham reinfusion plasmaphersis. In the present communication we report the effects of these procedures on T lymphocytes in peripheral mononuclear cells, proliferative responses to mitogens, allogeneic mixed lymphocyte reaction and cell-mediated lympholysis, as well as the effect of plasmapheresis on the spontaneous and pokeweed mitogen induced immunoglobulin secreting cells in peripheral blood. Several mononuclear cell functions were abnormal at the beginning of the study but no ...
To date, the association of serum macrophage migration inhibitory factor (MIF) and serum adipokines with lupus nephritis is controversial. To assess the utility of serum MIF, leptin, adiponectin and resistin levels as markers of proteinuria and renal dysfunction in lupus nephritis. Cross-sectional study including 196 systemic lupus erythematosus (SLE) patients and 52 healthy controls (HCs). Disease activity was assessed by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Renal SLE involvement was investigated by renal-SLEDAI. MIF, adiponectin, leptin and resistin levels were quantified by ELISA. We assessed the correlations of quantitative variables by Spearman correlation (rs). Multivariable linear regression adjusted the variables associated with the severity of proteinuria. SLE patients had higher MIF (p = 0.02) and adiponectin (p | 0.001) than HCs. Patients with renal SLE involvement (n = 43) had higher adiponectin (19.0 vs 13.3 μg/mL, p = 0.002) and resistin (10.7 vs 8.9 ng/mL, p = 0
TY - JOUR. T1 - Accuracy of Anticardiolipin Antibodies in Identifying a History of Thrombosis Among Patients With Systemic Lupus Erythematosus. AU - Escalante, Agustín. AU - L. Brey, Robin. AU - D.Mitchell Jr., Braxton. AU - Dreiner, Ute. PY - 1995/6. Y1 - 1995/6. N2 - objective: To measure the accuracy of anticardiolipin antibodies (aCL) in identifying a history of thrombosis among patients with systemic lupus erythematosus (SLE) or the primary antiphospholipid syndrome (PAPS). patients and methods: Patients with SLE or PAPS who attended our rheumatology clinic between April 1992 and March 1994 were included in a retrospective analysis of the relationship between thrombotic events and aCL. All aCL measurements were performed in the same laboratory by enzyme-linked immunosorbent assay, blinded as to the presence or absence of thrombosis. The diagnostic accuracy of IgG, IgM, and IgA aCL was quantified by means of the receiver operating characteristic area under the curve (ROC AUC) for each ...
A patient is described in which an inherited defect in the synthesis of C2 complement component coexisted with the disease systemic lupus erythematosus. The family studies show evidence of the autosomal recessive nature of the inheritance of the C2 synthesis defect. Of particular interest was the finding of a great-aunt who also had homozygous C2 deficiency. This great-aunt suffered from discoid lupus erythematosus as well. The occurrence of various autoantibodies in the serum from the family members, the typing for blood groups, HL-A antigens, and some serum protein markers are reported and discussed. The C2 deficiency may be a critical defect in the host defenses to infection that predisposed to the development of autoimmune disease. ...
A case of a 42-year-old female with hyperthyroidism was subsequently diagnosed to have systemic lupus erythematosus with distal RTA. The clinical examination on admission showed swelling of the knee joints and the urinalysis showed pH 6.5, pro 3+. Her blood routine results were as follows: white blood cells 1.85×109/L, platelets 100×109/L, erythrocyte 3.06×1012/L. The serum potassium was 3.11 mmol/L, 24 hour urinary electrolyte: K 68.87 mmol/24 H, antinuclear antibodies (ANA) 1:1 000, speckled pattern. The anti-double stranded DNA antibody (anti-dsDNA), anti SS-A(52) antibody and anti SS-A(60) antibody were positive. The light microscopy and immunofluorescence showed diffuse proliferative lupus nephritis. These data were compatible with the diagnosis of systemic lupus erythematosus. The diagnosis of hyperthyroidism and distal RTA is clear. This report showed that other autoimmune disease in the diagnosis of hyperthyroidism should not be ignored.. ...
Background and Objectives: Belimumab (BEL) is a monoclonal antibody approved for the treatment of active systemic lupus erythematosus (SLE) but not for lupus nephritis (LN) and neuropsychiatric systemic lupus erythematosus (NPSLE). We aimed to assess BELs effects on these severe, potentially life-threatening manifestations.Methods: Retrospective observational cohort study using routine clinical data in a case series of patients with SLE receiving BEL.Results: Sixteen patients received BEL therapy for active SLE. Nine were excluded because they had no LN or NPSLE. Six suffered from LN, and one patient had NPSLE. All LN patients received BEL in addition to standard therapy including glucocorticoids, hydroxychloroquine, and mycophenolate mofetil in five cases, and tacrolimus in one case. Three patients with proteinuria >1,000 mg/g creatinine responded well (one complete, two partial renal responses); all other patients had decreasing proteinuria and a reduction in anti-dsDNA levels. The patient with NPSLE
TY - JOUR. T1 - A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan. AU - Weng, C. T.. AU - Chung, T. J.. AU - Liu, M. F.. AU - Weng, M. Y.. AU - Lee, C. H.. AU - Chen, J. Y.. AU - Wu, A. B.. AU - Lin, B. W.. AU - Luo, C. Y.. AU - Hsu, S. C.. AU - Lee, B. F.. AU - Tsai, H. M.. AU - Chao, S. C.. AU - Wang, J. Y.. AU - Chen, T. Y.. AU - Chen, C. W.. AU - Chang, H. Y.. AU - Wang, C. R.. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Since large-scale reports of pulmonary infarction in systemic lupus erythematosus (SLE) are limited, a retrospective study was performed for this manifestation in 773 hospitalized patients in southern Taiwan from 1999 to 2009. Pulmonary infarction was defined as the presence of pulmonary embolism, persistent pulmonary infiltrates, and characteristic clinical symptoms. Demographic, clinical, laboratory, and radiological images data were analyzed. There were 12 patients with pulmonary embolism and 9 of them had ...
TY - JOUR. T1 - Cochlear Histopathologic Findings in Patients With Systemic Lupus Erythematosus. T2 - A Human Temporal Bone Study. AU - Kariya, Shin. AU - Kaya, Serdar. AU - Hizli, Ömer. AU - Hizli, Pelin. AU - Nishizaki, Kazunori. AU - Paparella, Michael M.. AU - Cureoglu, Sebahattin. PY - 2016/4/2. Y1 - 2016/4/2. N2 - HYPOTHESIS:: We hypothesized that, in archived human temporal bone samples from patients with systemic lupus erythematosus (SLE), a pathologic condition exists in the stria vascularis and cochlear hair cells. BACKGROUND:: Sensorineural hearing loss is a common feature in SLE patients. However, the pathophysiologic mechanism of cochlear dysfunction is unclear. METHODS:: We examined 15 temporal bone samples from 8 SLE patients, along with 17 samples from 10 age-matched healthy control patients. The samples were serially sectioned in the horizontal plane and stained with hematoxylin and eosin. We determined the area of the stria vascularis in a midmodiolar section of each cochlear ...
TY - JOUR. T1 - Autoimmune hepatitis with raised alpha-fetoprotein level as the presenting symptoms of systemic lupus erythematosus. T2 - A case report. AU - Liu, Feng Cheng. AU - Chang, Deh Ming. AU - Lai, Jenn Haung. AU - Lin, Chih Kung. AU - Chen, Hsiang Cheng. AU - Hou, Tsung Y.. AU - Kuo, San Yuan. PY - 2007/3/1. Y1 - 2007/3/1. N2 - Systemic lupus erythematosus (SLE) and autoimmune hepatitis are distinct clinical disorders, which rarely occur, in the same patient. We describe a 59-year-old woman with coexistence of both conditions. Photosensitivity, arthritis, positive ANA, and extreme elevation of anti-dsDNA concluded the diagnosis of SLE. Hyperbilirubinemia, high serum value of liver function, and elevation of alpha-fetoprotein were also prominent. By a review of pertinent literature, clinical investigation, calculation of autoimmune hepatitis score, and pathology of liver biopsy specimen, we were in favor of autoimmune hepatitis. Awareness of this rare presentation may be beneficial to ...
TY - JOUR. T1 - Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. AU - Hall, S.. AU - McCormick, J. L.. AU - Greipp, P. R.. AU - Michet, C. J.. AU - McKenna, C. H.. PY - 1985/1/1. Y1 - 1985/1/1. N2 - Fourteen patients with systemic lupus erythematosus had splenectomies done between 1960 and 1982 for treatment of severe thrombocytopenia. Thrombocytopenia persisted or recurred within 1 month postoperatively in five patients and within 6 months in three others. Three patients had late recurrence (18, 30, and 54 months after splenectomy); in two cases it was probably related to withdrawal of immunosuppressive agents or corticosteroids. Median lowest platelet count before splenectomy and median platelet count at relapse or failure of splenectomy were both 8000/μL. Only two patients maintained normal platelet counts without need for corticosteroids or other treatment. These results differ from those in patients with idiopathic thrombocytopenic purpura. Other treatments ...
TY - JOUR. T1 - Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus. T2 - A double blind, placebo controlled pilot study. AU - Tam, Lai S.. AU - Li, Edmund K.. AU - Leung, Vivian Y.F.. AU - Griffith, James F.. AU - Benzie, Iris F.F.. AU - Lim, Pak L.. AU - Whitney, Bruce. AU - Lee, Vivian W.Y.. AU - Lee, Kenneth K.C.. AU - Thomas, G. Neil. AU - Tomlinson, Brian. N1 - Copyright: Copyright 2010 Elsevier B.V., All rights reserved.. PY - 2005/2. Y1 - 2005/2. N2 - Objective. Patients with systemic lupus erythematosus (SLE) experience excess morbidity and mortality due to coronary artery disease (CAD) that cannot be fully explained by the classical CAD risk factors. Among emerging CAD risk factors, oxidative stress is currently being emphasized. We evaluated the effects of longterm antioxidant vitamins on markers of oxidative stress and antioxidant defense and endothelial function in 39 patients with SLE. Methods. Patients were ...
Title:Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus. VOLUME: 16 ISSUE: 2. Author(s):Johanna Pedroza-Díaz*, Tania Paola Luján Chavarria, Carlos Horacio Muñoz Vahos, Diego Francisco Hernández Ramírez, Elizabeth Olivares-Martínez, Gloria Vásquez, Luis Llorente, Hilda Fragoso-Loyo, Sarah Röthlisberger and Blanca Lucía Ortiz Reyes. Affiliation:Instituto Tecnologico Metropolitano-ITM-, Facultad de Ciencias Exactas y Aplicadas, Grupo de Investigacion e Innovacion Biomedica GI2B, Medellín, Universidad de Antioquia, Facultad de Medicina, Grupo de Inmunologia Celular e Inmunogenetica-GICIG-, Medellin, Universidad de Antioquia, Facultad de Medicina, Grupo de Reumatologia Universidad de Antioquia - GRUA-, Medellín, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Department of Immunology & Rheumatology, Mexico DF, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Department of Immunology & ...
TY - JOUR. T1 - Hypercementosis. T2 - A rare finding in a patient with systemic lupus erythematosus. AU - Shoor, Hitesh. AU - Sujir, Nitha. AU - Mutalik, Sunil. AU - Pai, Keerthilatha M.. PY - 2014/11/26. Y1 - 2014/11/26. N2 - Hypercementosis is excessive deposition of non-neoplastic cementum over normal root cementum, which alters root morphology. This cementum may be either hypocellular or cellular in nature. The aetiopathogenesis of hypercementosis is ambiguous. Although most of the cases are idiopathic, several local and systemic factors are also linked to this condition, such as Pagets disease, acromegaly, vitamin A deficiency, etc. We report two rare cases of hypercementosis associated with systemic lupus erythematosus, not previously described in the literature, and also discuss the possible aetiopathogenesis.. AB - Hypercementosis is excessive deposition of non-neoplastic cementum over normal root cementum, which alters root morphology. This cementum may be either hypocellular or ...
Discusses lupus, an autoimmune disorder. Focuses on systemic lupus erythematosus (SLE). Covers symptoms and how it is diagnosed. Covers treatment with medicines like corticosteroids, NSAIDs, and antimalarials. Discusses the importance of good self-care.
Neuropsychiatric symptoms affect nearly half of the patients with systemic lupus erythematosus; however, the effect on disease severity, quality of life, and prognosis is tremendous. Symptoms of neuropsychiatric systemic lupus erythematosus may range from mild diffuse ones, to acute life threatening events. Although the underlying mechanisms are still largely unraveled, several pathogenic pathways are identified, such as antibody-mediated neurotoxicity, vasculopathy due to anti-phospholipid antibodies and other mechanisms, and cytokine-induced neurotoxicity. In the current review, we describe the old and the new regarding epidemiology, pathophysiology, diagnosis, and management of neuropsychiatric systemic lupus erythematosus. The possible link between neuropsychiatric symptoms and specific mechanisms may help to facilitate our understanding of the disease in the future, thus allowing for better treatment strategies.
TY - JOUR. T1 - IgG and IgM autoantibody differences in discoid and systemic lupus patients. AU - Chong, Benjamin F.. AU - Tseng, Lin Chiang. AU - Lee, Thomas. AU - Vasquez, Rebecca. AU - Li, Quan Z.. AU - Zhang, Song. AU - Karp, David R.. AU - Olsen, Nancy J.. AU - Mohan, Chandra. PY - 2012/12. Y1 - 2012/12. N2 - Systemic lupus erythematosus (SLE) patients with discoid lupus erythematosus (DLE) were reported to have milder disease. To test this observation, we used sandwich arrays containing 98 autoantigens to compare autoantibody profiles of SLE subjects without DLE (DLE-SLE\+) (N = 9), SLE subjects with DLE (DLE\+SLE+) (N = 10), DLE subjects without SLE (DLE+SLE-) (N = 11), and healthy controls (N = 11). We validated differentially expressed autoantibodies using immunoassays in DLE-SLE+ (N = 18), DLE+SLE+ (N = 17), DLE+SLE-(N = 23), and healthy subjects (N = 22). Arrays showed 15 IgG autoantibodies (10 against nuclear antigens) and 4 IgM autoantibodies that were differentially expressed ...
The purpose of this study was to investigate whether white matter microstructure is altered in patients suffering from systemic lupus erythematosus (SLE), and if so, whether such alterations differed between patients with and without neuropsychiatric symptoms. Structural MRI and diffusion tensor imaging (DTI) were performed in 64 female SLE patients (mean age 36.9 years, range 18.2-52.2 years) and 21 healthy controls (mean age 36.7 years, range 23.3-51.2 years) in conjunction with clinical examination, laboratory tests, cognitive evaluation, and self-assessment questionnaires. The patients were subgrouped according to the American College of Rheumatology Neuropsychiatric Systemic Lupus Erythematosus case definitions into non-neuropsychiatric SLE (nonNPSLE) and neuropsychiatric SLE (NPSLE). Comparisons between the SLE group and healthy controls showed that the mean fractional anisotropy (FA) was significantly reduced in the right rostral cingulum (p = 0.038), the mid-sagittal corpus callosum (CC) ...
Systemic lupus erythematosus (SLE) is a systemic inflammatory disease. Clinically, the distinction between ongoing inflammation attributed to SLE, and organ damage due to medication or co-morbidities remains challenging. In addition, SLE is a heterogeneous disease where the various disease phenotypes complicate the search for biomarkers that adequately reflect disease activity and/or signs of increasing organ damage. The aim of the thesis was to investigate and evaluate potential new biomarkers of disease activity and/or organ damage in SLE patients.. High mobility group box protein-1 (HMGB1) is a nuclear non-histone protein that can shuttle to the cytoplasm, become secreted extracellularly, and participate in systemic inflammation. Administration of monoclonal anti-HMGB1 antibodies has been reported both to attenuate and intensify disease in animal models of arthritis and lupus. In Paper I of the thesis, circulating anti-HMGB1 was found in 23% of the SLE patients and correlated with disease ...
Publication date: September 2019Source: Advances in Chronic Kidney Disease, Volume 26, Issue 5Author(s): Elizabeth S. Kotzen, Sanjeet Roy, Koyal JainAntiphospholipid syndrome (APS) and other causes of thrombotic microangiopathy (TMA) negatively impact the renal outcomes of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Here we review the diagnosis and management of occlusive...
TY - JOUR. T1 - Altered type II interferon precedes autoantibody accrual and elevated type i interferon activity prior to systemic lupus erythematosus classification. AU - Munroe, Melissa E.. AU - Lu, Rufei. AU - Zhao, Yan D.. AU - Fife, Dustin A.. AU - Robertson, Julie M.. AU - Guthridge, Joel M.. AU - Niewold, Timothy B.. AU - Tsokos, George C.. AU - Keith, Michael P.. AU - Harley, John B.. AU - James, Judith A.. N1 - Publisher Copyright: © 2016 Published by the BMJ Publishing Group Limited.. PY - 2016/11/1. Y1 - 2016/11/1. N2 - Objectives The relationship of immune dysregulation and autoantibody production that may contribute to systemic lupus erythematosus (SLE) pathogenesis is unknown. This study evaluates the individual and combined contributions of autoantibodies, type I interferon (IFN-α) activity, and IFN-associated soluble mediators to disease development leading to SLE. Methods Serial serum specimens from 55 individuals collected prior to SLE classification (average timespan=4.3a ...
Haque, Sahena, Gordon, Caroline, Isenberg, David, Rahman, Anisur, Lanyon, Peter, Bell, Aubrey, Emery, Paul, McHugh, Neil, Teh, Lee Suan, Scott, David G. I., Akil, Mohamed, Naz, Sophia, Andrews, Jacqueline, Griffiths, Bridget, Harris, Helen, Youseff, Hazem, McLaren, John, Toescu, Veronica, Devakumar, Vinodh, Teir, Jamal and Bruce, Ian N. (2010) Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. Journal of Rheumatology, 37 (2). pp. 322-329. Full text not available from this repository. (Request a copy ...
OBJECTIVE: To determine whether variant alleles in the coding portion of the mannose-binding lectin (MBL) gene are associated with increased susceptibility to systemic lupus erythematosus (SLE) and concomitant infections. METHODS: MBL alleles and serum concentrations were determined by polymerase chain reaction and enzyme-linked immunosorbent assay, respectively, in 91 Danish patients with SLE and in 250 controls. RESULTS: Homozygosity for MBL variant alleles was observed in 7.7% of the SLE patients compared with 2.8% of the controls (P = 0.06), while no difference was seen for heterozygosity (33.0% versus 34.4%). Homozygotes had an increased risk of acquiring serious infections compared with patients who were heterozygous or homozygous for the normal allele (odds ratio 8.6, 95% confidence interval 1.5-47.6, P = 0.01). The time interval from the diagnosis of SLE to the first infectious event was shorter (P = 0.017), and the annual number of infectious events was 4 times higher, among homozygotes (P = 0
1. van Vollenhoven RF, Morabito LM, Engleman EG, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol. 1998;25:285-289. 2. van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus. 1999;8:181-187. 3. Mease PJ, Merrill JT, Lahita R, et al. GL701 (prasterone, dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erythematosus. Presented at: The Endocrine Societys 82nd Annual Meeting; June 21-24, 2000; Toronto, Canada.. 4. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97:4279-4284. 5. Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina and endometrium in postmenopausal women. J Clin ...
This case report finds that anti-type VII collagen autoantibodies can precede the clinical appearance of bullous systemic lupus erythematosus.
A patient with systemic lupus erythematosus (SLE) developed attacks of unilateral cataplexy precipitated by laughter. Unilateral cataplexy has not been described previously in detail and its association with SLE is unique. The clinical details, investigations, and diagnostic criteria are discussed and a causal relationship between cataplexy and SLE is suggested.. ...
Systemic lupus erythematosus is a rare, chronic autoimmune condition that can affect different parts of the body, such as the kidneys, skin, joints and blood.
Lupus Erythematosus is a chronic autoimmune disease that causes the immune system to attack ones body. The disease is characterized by the inflammation of various healthy tissues and organs in the body, including the joints, skin, kidneys, heart, lungs, blood vessels and brain. The severity of the disease may vary because no two cases of lupus are exactly alike.. What are the different types of Lupus?. Systemic Lupus Erythematosus (SLE) is the type of the disease that can affect many parts of the body. SLE is the most common form of the disease and is most commonly characterized by inflammation to the joints, skin, kidneys, heart, lungs, blood vessels and brain.. Cutaneous Lupus Erythematosus is a chronic skin disorder than can affect the skin. Patients with Cutaneous Lupus develop photosensitivity, hair loss, skin rashes and skin lesions.. Drug-Induced Lupus Erythematosus, like SLE, can affect many parts of the body. However, Drug-Induced Lupus is caused by an overreaction to certain ...
misc{08a586d2-6965-44d0-b083-93b1aacff9f7, author = {Magnusson, V and Zunec, R and Odeberg, J and Sturfelt, Gunnar and Truedsson, Lennart and Alarcon-Riquelme, ME}, issn = {1529-0131}, language = {eng}, number = {4}, pages = {1348--1350}, publisher = {John Wiley & Sons}, series = {Arthritis and Rheumatism}, title = {Polymorphisms of the Fc gamma receptor type IIB gene are not associated with systemic lupus erythematosus in the Swedish population}, url = {http://dx.doi.org/10.1002/art.20151}, volume = {50}, year = {2004 ...
Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016 is a market research report available at US $2500 for a Single User PDF License from RnR Market Research Reports Library.
JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND , 2019. The authors described a case of Candida parapsilosis cellulitis in a systemic lupus erythematosus patient presented with a clinical of cellulitis unresponsive to antibiotic treatment. Yeast cells and pseudohyphae were seen in tissue biopsy and C. parapsilosis were identified by tissues culture. There was excellent outcome after surgical debridement and antifungal treatment ...
Background: Lupus erythematosus (LE) is a heterogeneous disease ranging from mainly skin-restricted manifestations (discoid LE [DLE] and subacute cutaneous LE) to a progressive multisystem disease (systemic LE [SLE]). Genetic association studies have recently identified several strong susceptibility genes for SLE, including integrin alpha M (ITGAM), also known as CD11b, whereas the genetic background of DLE is less clear. Principal Findings: To specifically investigate whether ITGAM is a susceptibility gene not only for SLE, but also for cutaneous DLE, we genotyped 177 patients with DLE, 85 patients with sporadic SLE, 190 index cases from SLE families and 395 population control individuals from Finland for nine genetic markers at the ITGAM locus. SLE patients were further subdivided by the presence or absence of discoid rash and renal involvement. In addition, 235 Finnish and Swedish patients positive for Ro/SSA-autoantibodies were included in a subphenotype analysis. Analysis of the ITGAM ...
An antinuclear antibody (ANA) test measures the amount and pattern of antibodies in your blood that work against your own body (autoimmune reaction).. The bodys immune system normally attacks and destroys foreign substances such as bacteria and viruses. But in disorders known as autoimmune diseases, the immune system attacks and destroys the bodys normal tissues. When a person has an autoimmune disease, the immune system produces antibodies that attach to the bodys own cells as though they were foreign substances, often causing them to be damaged or destroyed. Rheumatoid arthritis and systemic lupus erythematosus are examples of autoimmune diseases.. An ANA test is used along with your symptoms, physical examination, and other tests to find an autoimmune disease.. ...
Looking for online definition of malar rash in the Medical Dictionary? malar rash explanation free. What is malar rash? Meaning of malar rash medical term. What does malar rash mean?
Objective: An Italian multicentre study was promoted in order to assess the accuracy of four anti-double-stranded DNA (dsDNA) antibody assays for SLE diagnosis and monitoring. Methods: Two hundred and twenty-three patients with established SLE according to ACR classification criteria were enrolled from 9 centres. They included 59 patients at first evaluation (disease duration ,12 months) and 164 with longer disease duration (median disease duration 120 months). The sera from 55 healthy subjects and 161 patients with rheumatic, infectious or neoplastic diseases were tested as controls. SLE activity was measured by ECLAM score. Anti-dsDNA antibodies were detected in serum by means of FarrzymeTM assay, fluoroenzymeimmunoassay (EliATM), Crithidia luciliae indirect immunofluorescence (CLIFT) or Farr radioimmunoassay (Farr). Cut-off values of quantitative assays were chosen by ROC curves analysis. Statistics were conducted by SPSS software package. Results: Sensitivity for SLE diagnosis ranged between ...
TY - JOUR. T1 - Total knee replacement in a patient with lupus anticoagulant.. AU - Bhagia, U. T.. AU - Corpe, Raymond S. AU - Steflik, D.. PY - 1997/1/1. Y1 - 1997/1/1. N2 - The lupus anticoagulant is an acquired circulating anticoagulant that was first described in patients with systemic lupus erythematosus (SLE). This rare hematologic entity is seen in about 1% to 2% of the general population and about 10% to 35% of the patients with SLE. Although associated with a prolonged partial thromboplastin time (PTT), the lupus anticoagulant does not cause bleeding complications but may be associated with an increase in thromboembolic complications. This report is presented to alert orthopedic surgeons of the increased risk of thromboembolic disease with a paradoxically prolonged PTT in patients with the lupus anticoagulant.. AB - The lupus anticoagulant is an acquired circulating anticoagulant that was first described in patients with systemic lupus erythematosus (SLE). This rare hematologic entity ...
Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies Elvira Bangert,1 Laura Wakani,2 Mehveen Merchant,3 Vibeke Strand,4 Zahi Touma2 1Division of Rheumatology, Department of Medicine, Queen’s University, Kingston, ON, Canada; 2University of Toronto Lupus Clinic, Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto, ON, Canada; 3Division of Rheumatology, Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada; 4Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune, multisystem rheumatic disease with significant impact on health-related quality of life (HRQoL). Patient-reported outcomes (PROs) provide valuable data on patient perceptions across a variety of domains, such as HRQoL, pain, fatigue, and depression. The measurement and results of PROs with respect to HRQoL in randomized controlled trials
Genetic epistasis of IL23/IL17 pathway genes in Crohns disease. [PMID 19306001] No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus. [PMID 19522770] Variants of the IL23R gene are associated with ankylosing spondylitis but not with Sjogren syndrome in Hungarian population samples. [PMID 19757086] Interleukin-23 receptor gene variants in Hungarian systemic lupus erythematosus patients. [PMID 19916168 ...
Systemic lupus erythematosus[edit]. Main article: Systemic lupus erythematosus and pregnancy. Systemic lupus erythematosus and ...
Role in systemic lupus erythematosus diagnosis[edit]. The kinetoplast found in C.luciliae allows them to be used for the ... "The Crithidia luciliae kinetoplast immunofluorescence test in systemic lupus erythematosus". Clin. Exp. Immunol. 25 (3): 480-6 ... The presence of this kinetoplast means they are important in the diagnosis of systemic lupus erythamatosus (SLE). By using C. ... indicating the presence of anti-dsDNA antibodies in a person with systemic lupus erythamatosus.. ...
Systemic lupus erythematosus In coeliac disease & dermatitis herpetiformis[edit]. Prior to refined typing for HLA-DQ and DR, ... In systemic lupus erythromatosus[edit]. The "HL-A1,8 phenotype" was found to be associated with severe systemic lupus ... In systemic lupus erythematosus (SLE) patients HLA DR3-DQ2.5-C4AQ0, which was strongly associated with SLE (odds ratio [OR] 2.8 ... Goldberg MA, Arnett FC, Bias WB, Shulman LE (1976). "Histocompatibility antigens in systemic lupus erythematosus". Arthritis ...
Systemic lupus erythematosus. *Paroxysmal nocturnal hemoglobinuria (blood test). *Viral infections (such as HIV, EBV; an ...
... systemic lupus erythematosus), myasthenia gravis, inclusion body myositis, Sjögren syndrome, and narcolepsy.[7] HLA typing has ... Jane Salmon; Wallace, Daniel J.; Dubois, Edmund L.; Kirou, Kyriakos A.; Hahn, Bevra; Lehman, Thomas A. (2007). Dubois' lupus ... erythematosus. Philadelphia: Lippincott Williams & Wilkins. ISBN 0-7817-9394-7.. *^ Margaritte-Jeannin P, Babron MC, Bourgey M ... "Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis". Human Molecular Genetics ...
Systemic lupus erythematosus DR3 3 45 20 0.31 Multiple sclerosis DR2 4 60 20 0.5 ...
Systemic lupus erythematosus: this autoimmune disease can affect a number of organs, among them the kidney, due to the deposit ... May have features of the underlying cause, such as the rash associated with systemic lupus erythematosus, or the neuropathy ... this is the same mechanism as occurs in systemic lupus erythematosus.. *HIV: the virus's antigens provoke an obstruction in the ... The disease can also cause lupus nephritis.. *Sarcoidosis: This disease does not usually affect the kidney but, on occasions, ...
... and Systemic Lupus Erythematosus (commonly referred to simply as lupus).[32][33][34] However, since photosensitivity occurs in ... HLA DR2 is strongly positively correlated with Systemic Lupus Erythematosus, narcolepsy[11] and multiple sclerosis, and ... lessons from systemic lupus erythematosus". Trends Mol Med. 18 (2): 101-108. doi:10.1016/j.molmed.2011.10.005. PMC 3278563. ... systemic lupus erythematosus (SLE), Sjögren's syndrome, eosinophilic granulomatosis with polyangiitis, Hashimoto's thyroiditis ...
Systemic lupus erythematosus (SLE). *Angioedema. *Acute glaucoma. *Panophthalmitis. *Orbital cellulitis. *Gonorrheal ...
Application to diagnosis and classification of systemic lupus erythematosus". The American Journal of Medicine. 74 (2): 206-16 ... This allows the use of ANAs in the diagnosis of some autoimmune disorders, including systemic lupus erythematosus, Sjögren ... These disorders include: systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, scleroderma, polymyositis ... A significant number of patients are diagnosed as systemic lupus erythematosus or undifferentiated connective tissue disease ...
ACR criteria for systemic lupus erythematosus. *Centor criteria for strep throat. Clinical decision support system[edit]. ...
... in systemic lupus erythematosus it is 4 to 14%,[97] and in sickle cell disease, it ranges from 20 to 40%.[98] Up to 4% of ... "Pulmonary Manifestations of Systemic Lupus Erythematosus". Seminars in Respiratory and Critical Care Medicine. MedScape. 35 (2 ... In systemic scleroderma, the incidence has been estimated to be 8 to 12% of all patients;[95] in rheumatoid arthritis it is ... Signs of systemic congestion resulting from right-sided heart failure include jugular venous distension, ascites, and ...
Doherty, N. E.; Siegel, R. J. (1985). "Cardiovascular manifestations of systemic lupus erythematosus". Am Heart J. 110 (6): ... is a form of nonbacterial endocarditis that is seen in association with systemic lupus erythematosus. It is one of the most ... Libman-Sacks endocarditis and a higher risk for embolic cerebrovascular disease in people with systemic lupus erythematosus ( ... common heart-related manifestations of lupus (the most common being pericarditis).[1] ...
Dale RC; Tang SP; Heckmatt JZ; Tatnall FM (2000). "Familial systemic lupus erythematosus and congenital infection-like syndrome ... Aicardi, J; Goutieres, F (2000). "Systemic lupus erythematosus or Aicardi-Goutieres syndrome?". Neuropediatrics. 31: 113. doi: ... and some characteristics of the condition also overlap with the autoimmune disease systemic lupus erythematosus (SLE). ...
Tsokos GC, Gordon C, Smolen JS (2007). Systemic lupus erythematosus: a companion to Rheumatology. Elsevier Health Sciences. pp ... The prognosis of mixed connective tissue disease is in one third of cases worse than that of systemic lupus erythematosus (SLE ... Differential diagnosis CPT2 MCTD combines features of scleroderma, myositis, systemic lupus erythematosus, and rheumatoid ... together with a mix of symptoms of systemic lupus erythematosus (SLE), scleroderma, and polymyositis.[2] The idea behind the " ...
... lessons from systemic lupus erythematosus". Trends Mol Med. 18 (2): 101-108. doi:10.1016/j.molmed.2011.10.005. PMC 3278563 . ...
"The pathogenesis of systemic lupus erythematosus-an update". Curr Opin Immunol. 24 (6): 651-657. doi:10.1016/j.coi.2012.10.004 ... resulting in syndromes such as systemic lupus erythematosus,[3] rheumatoid arthritis, type 1 diabetes,[4] autoimmune ... The systemic effects of oral tolerance may be explained by the extensive recirculation of immune cells primed in one mucosal ... The hypo-responsiveness induced by oral exposure is systemic, and can reduce hypersensitivity reactions in certain cases. ...
Collagen vascular diseases (e.g. systemic lupus erythematosus). *Dehydration. *Glomerular diseases, such as membranous ...
Phang KF, Cho J, Lee W, Mak A (2018). "Glucocorticoid-induced osteoporosis in systemic lupus erythematosus". Rheumatology ... Methylprednisolone is used to treat several rheumatic diseases, such as Systemic Lupus Erythematosus (SLE) and Rheumatoid ... "Systemic lupus erythematosus". Nat Rev Dis Primers. 2: 16039. doi:10.1038/nrdp.2016.39. PMID 27306639. S2CID 2628865. Chan TM ( ... systemic lupus erythematosus, acute and subacute bursitis, synovitis of osteoarthritis, post-traumatic osteoarthritis, and ...
Estes, Dorothy; Christian, Charles L. (1971). "The Natural History of Systemic Lupus Erythematosus by Prospective Analysis". ... Tsokos, George C. (2011). "Systemic Lupus Erythematosus". New England Journal of Medicine. 365 (22): 2110-21. doi:10.1056/ ... may be a forme fruste of systemic lupus erythematosus (SLE) associated optic neuropathy. AON is more than the presence of any ... "Optic Neuropathy and Chiasmopathy in the Diagnosis of Systemic Lupus Erythematosus". Journal of Neuro-Ophthalmology. 21 (3): ...
Systemic lupus erythematosus. The Systemic Lupus Erythematosus Quality of Life measure (L-QoL or SLEQoL) was published in 2009 ... Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life ... Yazdany J (November 2011). "Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of ... a quality-of-life instrument specific to systemic lupus erythematosus". Annals of the Rheumatic Diseases. 68 (2): 196-200. doi: ...
Jones JM, Martinez AJ, Joshi VV, McWilliams N (March 1975). "Systemic lupus erythematosus". Archives of Pathology. 99 (3): 152- ... These, or similar, bodies have been found increased in the presence of lymphoid cancers and SLE (lupus). They are also observed ...
... such as systemic lupus erythematosus or scleroderma. Latent lupus and incomplete lupus are alternative terms that have been ... such as systemic lupus erythematosus (SLE); systemic sclerosis (SSc); dermatomyositis (DM); polymyositis (PM); anti-synthetase ... It can occur alone or with rheumatoid arthritis, scleroderma, or systemic lupus erythematosus. Nine out of 10 cases occur in ... "Systemic lupus erythematosus". Genetics Home Reference. Retrieved 2019-11-19. Reference, Genetics Home. "Rheumatoid arthritis ...
Systemic lupus erythematosus is associated with focal cancers throughout the body and lymphoproliferative cancers. Systemic ... Conversely, systemic lupus erythematosus is correlated with a decrease in some cancers. This is best explained by increased ... This test is most useful for diagnosing systemic lupus erythematosus, having a 95% positive test rate. A test taking ... Tsokos GC (December 2011). "Systemic lupus erythematosus". The New England Journal of Medicine. 365 (22): 2110-21. doi:10.1056/ ...
... and pancreatic disorders in systemic lupus erythematosus.". Systemic Lupus Erythematosus. Academic Press. pp. 391-401. doi: ... and Pancreatic Disorders in Systemic Lupus Erythematosus", Systemic Lupus Erythematosus, Elsevier, pp. 391-401 Gosemann JH, ...
"Systemic Lupus Erythematosus. Lupus treatment; information , Patient". Patient. Retrieved 21 September 2016. " ... Systemic lupus erythematosus is associated with low C3 and C4. Membranoproliferative glomerulonephritis usually has low C3. The ... C4: C4 deficiency is highly associated with systemic lupus erythematosus. Aβ42, a protein involved in Alzheimer's disease, can ...
In systemic lupus erythematosus, the Zap-70 receptor pathway is missing and Syk takes its place. ZAP-70 deficiency results in a ... Tsokos GC (December 2011). "Systemic lupus erythematosus". The New England Journal of Medicine. 365 (22): 2110-21. doi:10.1056/ ...
"Systemic Lupus Erythematosus - 4th Edition". www.elsevier.com. Retrieved 2018-08-20. "Why The Body Attacks Itself". Retrieved ... Neuropsychiatric Manifestations of Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 1999. Lahita, ... Novel Treatments for Systemic Lupus Erythematosus. Vol 3, no 5, pp255-266. Therapeutic Advances in Musculoskeletal Disease. ... Systemic Lupus Erythematosus. John Wiley & Sons, 1986. 2nd Edition, Churchill Livingstone, 1992. 3rd edition, Academic Press, ...
... systemic lupus erythematosus (SLE), scleroderma (systemic sclerosis or SSc), and pemphigus vulgaris (PV) with success for some ... D'Cruz DP, Khamashta MA, Hughes GR (February 2007). "Systemic lupus erythematosus". Lancet. 369 (9561): 587-96. CiteSeerX 10.1. ... Walsh proposed that mycophenolate should be considered as a first-line induction therapy for treatment of lupus nephritis in ... Its increasing application in treating lupus nephritis has demonstrated more frequent complete response and less frequent ...
Hill, L. C. (1957). "Systemic Lupus Erythematosus". BMJ. 2 (5046): 655-660 contd. doi:10.1136/bmj.2.5046.655. PMC 1962315. PMID ... Systemic Lupus Erythematosus 1958 John St. Clair Elkington, Cerebral Vascular Disease in the light of Modern Techniques 1959 ...
systemic lupus erythematosus. *tinea capitis. *loose anagen syndrome. *lichen planopilaris. *folliculitis decalvans ... Dessinioti C, Katsambas A, Antoniou C (May-June 2014). "Hidradenitis suppurrativa (acne inversa) as a systemic disease". ... due to negligible systemic absorption.[47][150] Nadifloxacin and dapsone (category C) are other topical antibiotics that may be ... "Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, ...
Two patients with systemic lupus erythematosus died of progressive multifocal leukoencephalopathy (PML) after being treated ... systemic lupus erythematosus, chronic inflammatory demyelinating polyneuropathy and autoimmune anemias.[16] The most dangerous ...
Systemic lupus erythematosus (SLE) - a major autoimmune disease of connective tissue. *Scurvy, caused by a deficiency of ...
... systemic lupus erythematosus, ANCA vasculitis), paraproteinemias (amyloidosis, multiple myeloma) and metabolic diseases ( ... Examples include acquired conditions such as systemic vasculitides (e.g. ANCA vasculitis) and autoimmune diseases (e.g., lupus ... Nephrology also studies systemic conditions that affect the kidneys, such as diabetes and autoimmune disease; and systemic ... Many diseases affecting the kidney are systemic disorders not limited to the organ itself, and may require special treatment. ...
autoimmune conditions (e.g., systemic lupus erythematosus[5]). *infections (e.g., syphilis, malaria, hepatitis B, hepatitis C) ... The antigens may be part of the basement membrane, or deposited from elsewhere by the systemic circulation. ... Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR (2016). "Cyclosporine for lupus membranous nephritis: experience ... with ten patients and review of the literature". Lupus. 9 (4): 241-51. doi:10.1191/096120300680198935. PMID 10866094.. ...
Systemic lupus erythematosus. *Temporal arteritis and Polymyalgia rheumatica. *Tenosynovitis.. Treatment[change , change source ...
Immune dysfunction - arthritis, systemic lupus erythematosus, Sjögren syndrome, myasthenia gravis, systemic vasculitis, Behcet- ...
Secondary antiphospholipid syndrome occurs with other autoimmune diseases, such as systemic lupus erythematosus (SLE). In rare ... most frequently systemic lupus erythematosus, SLE), and catastrophic (when there is simultaneous multi-organ failure with small ... syndrome responsible for most of the miscarriages in later trimesters seen in concomitant systemic lupus erythematosus and ... Lupus and Pregnancy Archived 2013-02-18 at the Wayback Machine. by Michelle Petri. The Johns Hopkins Lupus Center. Retrieved ...
Systemic connective tissue disorders (M32-M36, 710). General. Systemic lupus erythematosus. *Drug-induced SLE ...
... activity correlate with disease activity and have been implicated in autoimmune diseases including systemic lupus erythematosus ... and systemic DNA damage responses leading to malignancies.[124] ... "Quality control mechanisms in cellular and systemic DNA damage ...
systemic lupus erythematosus. *tinea capitis. *loose anagen syndrome. *lichen planopilaris. *folliculitis decalvans ...
Systemic lupus erythematosus. *Subacute bacterial endocarditis. *Rheumatoid arthritis. Type IV/cell-mediated. (T cells). ...
... lupus erythematosus, Hodgkin's lymphoma, myelodysplastic syndrome and more. Pomalidomide was submitted for FDA approval on ... EMA has already granted pomalidomide an orphan designation for primary myelofibrosis, MM, systemic sclerosis, post- ...
Systemic lupus erythematosus. *Subacute bacterial endocarditis. *Rheumatoid arthritis. Type IV/cell-mediated. (T cells). ... If the food is accidentally ingested and a systemic reaction (anaphylaxis) occurs, then epinephrine should be used. A second ... from their granules into the surrounding tissue causing several systemic effects, such as vasodilation, mucous secretion, nerve ...
Systemic lupus erythematosus. *Subacute bacterial endocarditis. *Rheumatoid arthritis. Type IV/cell-mediated. (T cells). ...
Permin H, Wiik A (1978). "The prevalence of IgE antinuclear antibodies in rheumatoid arthritis and systemic lupus erythematosus ... and atopic disorders in systemic lupus erythematosus". Allergy. 50 (1): 94-6. PMID 7741196.. ... IgE is known to be elevated in various autoimmune disorders such as Lupus(SLE), Rheumatoid Arthritis(RA) & psoriasis, and is ... Long-term uses of systemic corticosteroids are known to cause many serious side effects and are advisable to avoid, if ...
Maternal nutrition Nutrition and pregnancy Concomitant conditions Diabetes mellitus and pregnancy Systemic lupus erythematosus ...
Chronic conditions that can produce nephropathy include systemic lupus erythematosus, diabetes mellitus and high blood pressure ... LupusEdit. Despite expensive treatments, lupus nephritis remains a major cause of morbidity and mortality in people with ... "Lupus nephritis: a critical review". Autoimmunity Reviews. 12 (2): 174-194. doi:10.1016/j.autrev.2012.08.018. ISSN 1873-0183. ...
செம்முருடு அமைப்பு நோய் (Systemic lupus erythematosus) (SLE) ( இது இணைப்பிழையத்தின் முதன்மை தன் நோயெதிர்ப்பு நலிவு அல்லது நோய் ...
... systemic lupus erythematosus, rheumatoid arthritis, heart failure, reactive arthritis, ankylosing spondylitis and HIV. ... A variety of systemic diseases are associated with aggressive IgA nephropathy ( Berger's disease) such as liver failure, cancer ... Non-aggressive Berger's disease may also be associated with any of the above systemic diseases, however this is rare. ... Smith AC, Molyneux K, Feehally J, Barratt J (2006). "O-glycosylation of serum IgA1 antibodies against mucosal and systemic ...
Systemic lupus erythematosus. *Thyroid disorders. *Maternal death. *v. *t. *e. Index of obstetrics ...
Localized or diffuse hair loss may also occur in cicatricial alopecia (lupus erythematosus, lichen plano pilaris, folliculitis ... or systemic disease. Telogen hairs have tiny bulbs without sheaths at their roots. Telogen effluvium shows an increased ... lupus erythematosus, radiation therapy, and sarcoidosis.[2][3] Diagnosis of hair loss is partly based on the areas affected.[3] ...
Other conditions noted have been cement dermatitis, collagen deposits, discoid lupus erythematosus, eczematous eruptions, ... Papageorgiou PP, Hongcharu W, Chu AC (1999). "Systemic sarcoidosis presenting with multiple tattoo granulomas and an extra- ...
... a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY ...
Systemic lupus erythematosus · Subacute bacterial endocarditis · Rheumatoid arthritis. Type IV/cell-mediated. (T-cells). ... Sjögren's syndrome · Autoimmune hepatitis · Autoimmune polyendocrine syndrome (APS1, APS2) · Autoimmune adrenalitis · Systemic ...
... and Complement-Fixing Antibodies to DNA in Sera from Patients with Systemic Lupus Erythematosus". J Clin Invest. 46 (11): 1785- ...
Wikimedia Commons has media related to Systemic lupus erythematosus.. Look up systemic lupus erythematosus in Wiktionary, the ... Canine discoid lupus erythematosus in dogs. References. *^ a b c d e f g h i j k l m n o p q r s t u v "Handout on Health: ... Lupus Erythematosus: A review of the current status of Discoid and Systemic Lupus Erythematosus. New York: McGraw Hill. pp. 1-9 ... "Lupus. 15 (5): 308-18. doi:10.1191/0961203306lu2305xx. PMID 16761508.. *^ "Handout on Health: Systemic Lupus Erythematosus". ...
Learn about systemic lupus erythematosus (SLE), the most common type of lupus. ... Systemic lupus erythematosus (SLE), is the most common type of lupus. SLE is an autoimmune disease in which the immune system ... Lupus QoL-US benchmarks for US patients with systemic lupus erythematosus. J Rheumatol. 2010;37(9):1828-1833. doi:10.3899/ ... The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: The Manhattan Lupus ...
... systemic lupus erythematosus or NPSLE refers to the neurological and psychiatric manifestations of systemic lupus erythematosus ... 2010). "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report ... "Neuropsychiatric Syndromes in Systemic Lupus Erythematosus: A Meta-Analysis". Seminars in Arthritis and Rheumatism. 41 (1): 1- ... "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives". Drugs. 76 (4): 459- ...
Systemic lupus erythematosis is an autoimmune disease of unknown etiology (1-3). Clinical features include fatigue, fever, ... Systemic Lupus Erythematosus Lupus Nephritis Lupus Patient Congenital Heart Block Lupus Nephritis Patient These keywords were ... Dubois EL, ed: Lupus Erythematosus: A Review of the Current Status of Discoid and Systemic Lupus Erythematosus and Their ... Neonatal lupus erythematosus with cardiac involvement in offspring of mothers with experimenatal systemic lupus erythematosus. ...
... and guidelines on lupus, systemic lupus erythematosus (SLE). Recognize lupus symptoms and signs of lupus. Review articles on ... Systemic Lupus Erythematosus : Review in-depth clinical information, latest medical news, ... Bullous Systemic Lupus Erythematosus (BSLE) * Lupus Nephritis * Systemic Lupus Erythematosus (SLE) * Systemic Lupus ...
Systemic Lupus Erythematosus: Methods and Protocols describes a number of genetic, biochemical and immunological techniques. ... Systemic Lupus Erythematosus: Methods and Protocols describes a number of genetic, biochemical and immunological techniques. ... Authoritative and practical, Systemic Lupus Erythematosus: Methods and Protocols appeals to biomedical and clinical scientists ... Meta-analysis as a Diagnostic Tool for Predicting Disease Onset and/or Activity in Systemic Lupus Erythematosus ...
Systemic lupus erythematosus.. Tsokos GC1.. Author information. 1. Division of Rheumatology, Beth Israel Deaconess Medical ... Lupus Erythematosus, Systemic*/drug therapy. *Lupus Erythematosus, Systemic*/etiology. *Lupus Erythematosus, Systemic*/genetics ... Systemic lupus erythematosus. [N Engl J Med. 2012]. *Systemic lupus erythematosus. [N Engl J Med. 2012] ...
Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and ... SYSTEMIC LUPUS ERYTHEMATOSUS WITH HEMOLYTIC ANEMIA, SUSCEPTIBILITY TO, 1. *SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, ... SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY TO, 2. *SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS, SUSCEPTIBILITY ... medlineplus.gov/genetics/condition/systemic-lupus-erythematosus/ Systemic lupus erythematosus. ...
Systemic lupus erythematosus is a remarkable and challenging disorder. Its diversity of clinical features is matched by the ... Systemic lupus erythematosus.. Lisnevskaia L1, Murphy G2, Isenberg D3. ... Lupus Erythematosus, Systemic/diagnosis*. *Lupus Erythematosus, Systemic/drug therapy*. *Lupus Erythematosus, Systemic/ ...
... also called lupus or SLE) is a disease in which a persons immune system attacks and injures the bodys own organs and tissues ... Systemic lupus erythematosus. Definition. Systemic lupus erythematosus (also called lupus or SLE) is a disease in which a ... Systemic Lupus Erythematosus. Definition. Systemic lupus erythematosus (also called lupus or SLE) is a disease where a persons ... lupus.html,.. Hoffman, David L. "The Use of Herbs in the Treatment of Systemic Lupus Erythematosus." HealthWorld Online. [cited ...
Systemic lupus erythematosus in pregnancy brings risks for the mother, and possible harm to the fetus if the disease is treated ... She has systemic lupus erythematosus (SLE), diagnosed in 1998. The disease has affected predominantly her joints, but she did ... Systemic lupus erythematosus (SLE) is a multisystem relapsing and remitting autoimmune disease. The management of this ... Systemic lupus erythematosus. BMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39358.519491.AD (Published 01 November 2007) Cite ...
... Guest Editors: Chaim Putterman, Roberto Caricchio, Anne Davidson, and Harris Perlman *Systemic ... Systemic-Lupus-Erythematosus-Related Acute Pancreatitis: A Cohort from South China, Yanlong Yang, Yujin Ye, Liuqin Liang, ... Balance between Regulatory T and Th17 Cells in Systemic Lupus Erythematosus: The Old and the New, Alessia Alunno, Elena ... Modulatory Function of Invariant Natural Killer T Cells in Systemic Lupus Erythematosus, Yi-Ping Chuang, Chih-Hung Wang, Ning- ...
... validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. ... Systemic Lupus Erythematosus Contributor: Laura Tarter, MD Rheum2Learn cases contain links to images in the Rheumatology Image ... Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that may affect the skin, joints, kidneys, and other organs ... Recognize the clinical manifestations of systemic lupus erythematosus.. *Obtain an appropriate history to determine if a ...
Systemic lupus erythematosus (SLE, lupus) is the prototype of systemic autoimmune disease (AD). Immune system activation in SLE ... Systemic Lupus Erythematosus 2014. Juan-Manuel Anaya,1,2 Yehuda Shoenfeld,3 and Ricard Cervera4 ... M. Kiriakidou, D. Cotton, D. Taichman, and S. Williams, "Systemic lupus erythematosus," Annals of Internal Medicine, vol. 159, ... M. Gatto, N. Agmon-Levin, A. Soriano et al., "Human papillomavirus vaccine and systemic lupus erythematosus," Clinical ...
Guanoxan and Systemic Lupus Erythematosus. Br Med J 1967; 1 doi: https://doi.org/10.1136/bmj.1.5532.111-a (Published 14 January ...
Find Systemic Lupus Erythematosus information, treatments for Systemic Lupus Erythematosus and Systemic Lupus Erythematosus ... MedHelps Systemic Lupus Erythematosus Center for Information, Symptoms, Resources, Treatments and Tools for Systemic Lupus ... Her blog I write about Lupus, CFS/FMS journey: http://no2vaccines4mylittlepooker.blogspo... ...
Systemic lupus erythematosus: Systemic lupus erythematosus (SLE) is a syndrome characterized by organ damage that results from ... Systemic lupus erythematosus. Systemic lupus erythematosus (SLE) is a syndrome characterized by organ damage that results from ...
Some people develop a form of lupus that involves only the skin, called cutaneous lupus or discoid lupus erythematosus. Another ... While drug-induced lupus may cause rash, arthritis and fever that appear similar to the systemic form of lupus, it tends to be ... Lupus is relatively rare, affecting less than one in 2,000 people. The scientific name of the disease is systemic lupus ... Therefore, many experts now recommend antimalarial treatment for all patients with systemic lupus unless they cannot tolerate ...
... *Medical Editor: William C. Shiel Jr., MD, FACP, FACR ... Lupus Symptoms, Rash, and Treatment. What is Lupus? Learn about lupus symptoms like butterfly rash, joint pain and fatigue. ...
Parvovirus infection mimicking systemic lupus erythematosus. Mohan Cooray, Joshua J. Manolakos, Douglas S. Wright, Shariq ... Parvovirus infection mimicking systemic lupus erythematosus. Mohan Cooray, Joshua J. Manolakos, Douglas S. Wright, Shariq ... Systemic lupus erythematosus and parvovirus B19: Casual coincidence or causative culprit? Clin Rev Allergy Immunol 2003;25:41-8 ... Parvovirus infection mimicking systemic lupus erythematosus. Mohan Cooray, Joshua J. Manolakos, Douglas S. Wright, Shariq ...
Well show you photos to help you identify your symptoms and explain the causes of systemic lupus erythematosus. You can treat ... the most common form of lupus, is a chronic autoimmune disease that can cause severe fatigue and joint pain. ... There are many autoimmune diseases, including systemic lupus erythematosus (SLE). The term lupus has been used to identify a ... Systemic Lupus Erythematosus (SLE) Medically reviewed by Brenda B. Spriggs, MD, FACP - Written by Jaime Herndon - Updated on ...
Ask questions and get answers about Systemic Lupus Erythematosus. Our support group helps people share their own experience. ... Systemic Lupus Erythematosus Support Group. Related terms: Disseminated Lupus Erythematosus, Lupus, SLE ... Systemic Lupus Erythematosus - what do you use for hair loss related to lupus?. Updated 4 Jul 2017 • 10 answers ... Systemic Lupus Erythematosus - Does anyone else take Plaquenil for Lupus?. Updated 1 Mar 2019 • 13 answers ...
Systemic Lupus Erythematosus Clinical Research Trial Listings in Immunology Musculoskeletal Nephrology Rheumatology on ... Systemic Lupus Erythematosus Clinical Trials. A listing of Systemic Lupus Erythematosus medical research trials actively ... The Health Improvement and Prevention Program in Systemic Lupus Erythematosus The survival rate in Systemic Lupus Erythematosus ... Cyclophosphamide in Lupus Nephritis The autoimmune disease systemic lupus erythematosus (SLE) commonly affects the kidneys ( ...
Trends in Deaths from Systemic Lupus Erythematosus --- United States, 1979--1998. Systemic lupus erythematosus (SLE) is a ... McAlindon T. Update on the epidemiology of systemic lupus erythematosus: new spins on old ideas. Curr Opin Rheum 2000;12:104-- ... American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus. Guidelines for referral and management of ... Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheum 2001;13:345--51. ...
Helping you find trustworthy answers on Systemic Lupus Erythematosus , Latest evidence made easy ... Find all the evidence you need on Systemic Lupus Erythematosus via the Trip Database. ... Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with unknown aetiology. Epstein-Barr virus (EBV) is an ... Patients with systemic lupus erythematosus (SLE) are susceptible to herpes simplex virus (HSV) infection, which occasionally ...
Systemic Lupus Erythematosus. Systematic Lupus Erythematosus (SLE) is a chronic disease with a significantly improved life ... The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned. Maria Teruel and Marta E ... The critical role of epigenetics in systemic lupus erythematosus and autoimmunity. Hai Long, Heng Yin, Ling Wang, M. Eric ... A Childs HLA-DRB1 genotype increases maternal risk of systemic lupus erythematosus. Giovanna I. Cruz, Xiaorong Shao, Hong ...
Helping you find trustworthy answers on Systemic Lupus Erythematosus , Latest evidence made easy ... Find all the evidence you need on Systemic Lupus Erythematosus via the Trip Database. ... Systemic lupus erythematosus and hypertension. (Abstract). Systemic lupus erythematosus and hypertension. Systemic lupus ... Systemic Lupus Erythematosus and dysbiosis in the microbiome: cause or effect or both? (Abstract). Systemic Lupus Erythematosus ...
... , Lupus, SLE, Lupus Serositis, Lupus Nephritis, Lupus Cerebritis. ... Systemic lupus erythematosus, unspecified, SYSTEMIC LUPUS ERYTHEMATOSUS, SYSTEMIC LUPUS ERYTHEMATOSUS SYND, Systemic Lupus ... disseminated lupus erythematosus, lupus, systemic lupus erythematosus (diagnosis), systemic lupus, systemic lupus erythematosus ... Systemic lupus erythematosus, Systemic lupus erythematosus (disorder), erythematosus; lupus, systemic, lupus; erythematosus, ...
... (SLE) is a chronic inflammatory disease of unknown cause that can affect the skin, joints, kidneys ... 2006) Mortality in systemic lupus erythematosus. Arthritis and Rheumatism 54: 2550.. Boackle SA (2013) Advances in lupus ... Schur PH (1995) Genetics of systemic lupus erythematosus. Lupus 4: 425-437. ... Systemic Lupus Erythematosus, 4th edn. New York: Churchill Livingstone.. Schur PH and Massarotti EM (eds) (2012) Lupus ...
Systemic lupus erythematosus (SLE) is one of the disorders that is most common in women. SLE is associated with cerebrovascular ... How does systemic lupus erythematosus (SLE) cause stroke during pregnancy?) and How does systemic lupus erythematosus (SLE) ... Systemic lupus erythematosus (SLE) is one of the disorders that is most common in women. SLE is associated with cerebrovascular ... How does systemic lupus erythematosus (SLE) cause stroke during pregnancy?. Updated: Aug 20, 2019 ...
  • [1] There are a number of other kinds of lupus erythematosus including discoid lupus erythematosus , neonatal lupus , and subacute cutaneous lupus erythematosus . (wikipedia.org)
  • In addition to this general tendency, injury to the dermoepidermal junction by the interface dermatitis of cutaneous lupus erythematosus may expose new epitopes and precipitate the development of antibodies that specifically target the BMZ. (medscape.com)
  • This patient's biopsy reveals class IV lupus nephritis. (rheumatology.org)
  • Acceptable first-line therapies for active class III/IV lupus nephritis include mycophenolate mofetil or cyclophosphamide in addition to high-dose corticosteroids. (rheumatology.org)
  • The patient is also started on an ACE-inhibitor to reduce urinary protein excretion and control hypertension (which is often a problem with lupus nephritis), calcium and vitamin D for bone health, and omeprazole for gastric protection in the setting of prednisone use. (rheumatology.org)
  • The autoimmune disease systemic lupus erythematosus (SLE) commonly affects the kidneys (lupus nephritis) and for some patients leads to a progressive loss of kidney function. (centerwatch.com)
  • Patients with Lupus nephritis and refractory to corticosteroid or cyclophosphamide trials will be enrolled in this trial. (centerwatch.com)
  • Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. (elsevier.com)
  • Lupus nephritis: When and how often to biopsy and what does it mean? (elsevier.com)
  • Davidson A and Aranow C (2006) Pathogenesis and treatment of systemic lupus erythematosus nephritis. (els.net)
  • A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. (epnet.com)
  • In particular, certain genetic mutations have been associated with lupus nephritis (LN). Specific genetic factors have been evaluated in terms of their relation to other disease manifestations, such as neuropsychiatric symptoms, cutaneous symptoms, hematologic symptoms, and others. (uspharmacist.com)
  • Patients with systemic lupus erythematosus (SLE) often develop glomerulonephritis (i.e., inflammation in the glomeruli of the kidney), commonly referred to as lupus nephritis. (jci.org)
  • Patients with lupus nephritis typically have autoantibodies to the complement classical pathway protein C1q. (jci.org)
  • Whether these anti-C1q antibodies play any role in the development of lupus nephritis has been unclear. (jci.org)
  • Evidence from a Cochrane review of randomised controlled trials (RCTs) and quasi-RCTs suggests that mycophenolate mofetil is as effective as cyclophosphamide at inducing remission in lupus nephritis, but with a lower risk of ovarian failure. (nice.org.uk)
  • For maintenance therapy in lupus nephritis the Cochrane review found that mycophenolate mofetil was more effective than azathioprine for preventing relapse, with no increase in clinically important adverse events. (nice.org.uk)
  • A Cochrane review found that there was no overall difference for mortality or any renal outcome between mycophenolate mofetil and intravenous (up to 7 studies, n=up to 710) or oral (1 study, n=62) cyclophosphamide for induction therapy in lupus nephritis. (nice.org.uk)
  • The Cochrane review found that there was a higher risk of renal relapse in people with lupus nephritis maintained on azathioprine compared with those maintained on mycophenolate mofetil (3 studies, n=371, RR 1.83, 95% CI 1.24 to 2.71), but there was no statistically significant difference between them in mortality. (nice.org.uk)
  • For induction therapy in lupus nephritis, mycophenolate mofetil was found to be associated with a lower risk of toxic adverse events such as ovarian failure, alopecia and leucopenia, compared with cyclophosphamide. (nice.org.uk)
  • Does Renin‐Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? (sclero.org)
  • Our data do not support the hypothesis that ACE inhibitors/ARBs may be protective against atherosclerotic CVEs in lupus nephritis patients. (sclero.org)
  • AbstractObjectiveLupus nephritis (LN) is a major determinant of morbidity and mortality in systemic lupus erythematosus (SLE). (medworm.com)
  • Patients with severe active lupus nephritis or central nervous system lupus were excluded from the trials. (nice.org.uk)
  • More common scenarios where lupus needs to be considered in the pregnant or postpartum patient include onset of the characteristic malar rash, arthralgias, pleurisy, pericarditis, persistent unexplained fever or nephritis, as these could represent the initial lupus flare. (renalandurologynews.com)
  • Nephritis can have a number of other etiologies, and a renal biopsy may be helpful in identifying a characteristic histologic lesion for lupus. (renalandurologynews.com)
  • Lupus nephritis occurs in 60% of patients with systemic lupus erythematosus (SLE) and is classified into 6 categories. (medindia.net)
  • Lupus nephritis (LN) or lupus glomerulonephritis is a serious complication of SLE in which the kidneys are affected. (digitaljournal.com)
  • GlobalData epidemiologists provide the 10-year epidemiological forecast of the diagnosed prevalent cases of SLE segmented by sex and age and the diagnosed prevalent cases of lupus nephritis (LN) for the 7MM. (digitaljournal.com)
  • As many as 70% of people with lupus have some skin symptoms. (wikipedia.org)
  • People with lupus that get proper medical care, preventive care, and education can significantly improve function and quality of life. (cdc.gov)
  • Nearly all people with lupus have a positive test for antinuclear antibody (ANA). (medlineplus.gov)
  • If your doctor suspects you have lupus, he or she will order a blood test to look for a type of antibody, called the antinuclear antibody (ANA), that almost all people with lupus have in their blood. (womenshealthmag.com)
  • The disease isn't linked to a certain gene, but people with lupus often have family members with other autoimmune conditions. (healthline.com)
  • Although some people with lupus have only mild symptoms, the disease is lifelong and can become severe. (uwhealth.org)
  • For example, steroids like prednisone may cause mood symptoms in people with lupus. (hss.edu)
  • Generally, depression occurs in people with lupus just like it does with everyone else: because of some combination of genetics, frustration, the difficulties of life, etc. (hss.edu)
  • About 10 to 15 percent of people with lupus die due to complications. (emedicinehealth.com)
  • Heart attacks and other cardiovascular diseases are the leading causes of death in people with lupus. (emedicinehealth.com)
  • 1996) Remission of systemic lupus erythematosus. (els.net)
  • If you have lupus you will have periods of illness (flares) and periods of wellness (remission). (nih.gov)
  • Active systemic lupus erythematosus involves frequent flares and more severe symptoms compared with inactive disease which is when the disease is in remission. (nice.org.uk)
  • By contrast, the presence of antiphospholipid antibodies or lupus anticoagulant could not reliably predict the time of clotting, as these markers were usually not abnormal within 6 months before the clinical diagnosis of the clotting event. (medscape.com)
  • The American College of Rheumatology has developed classification criteria for lupus, used as a aid in the diagnosis of this complex multi-organ system disease, but primarily intended for use in studies. (rheumatology.org)
  • If you have had 4 of the 11 lupus criteria at some time during your illness, even if fewer than four are active at the time of diagnosis, the diagnosis is more certain and you may be eligible for entry into a research study of lupus. (womenshealthmag.com)
  • Lupus symptoms are also symptoms of many other diseases, which makes diagnosis tricky. (healthline.com)
  • Systematic Lupus Erythematosus (SLE) is a chronic disease with a significantly improved life expectancy due to early recognition, diagnosis, monitoring, and therapy of patients. (elsevier.com)
  • All 5 criteria listed above are needed for a diagnosis of type 1 bullous systemic lupus erythematosus, whereas only the first 4 criteria are needed to diagnose type 2 (undetermined location of antigen or dermal antigen other than type VII collagen) and type 3 (epidermal antigen) bullous systemic lupus erythematosus. (medscape.com)
  • In addition, onset of neuropsychiatric symptoms may happen prior to the diagnosis of lupus. (wikipedia.org)
  • To make the diagnosis of lupus, the patient should have multiple criteria listed in Table I, but no single symptom or laboratory test is necessary for the diagnosis. (renalandurologynews.com)
  • Rheumatology consult is often helpful in confirming a diagnosis of lupus and establishing a plan of care and long term followup. (renalandurologynews.com)
  • Antinuclear Antibody Testing for the Diagnosis of Systemic Lupus Erythematosus. (harvard.edu)
  • When the disease progresses and begins to involve one or multiple systems of the body, it achieves the diagnosis of systemic lupus erythematosus. (chiro.org)
  • Most people diagnosed with lupus can live a normal life span due to improvements in diagnosis and treatment. (emedicinehealth.com)
  • ABSTRACT: Systemic lupus erythematosus (SLE) is an autoimmune disease that causes inflammation throughout the body. (uspharmacist.com)
  • An abstract of the article "Associations of Antibodies Directed to ENA With HLA Class II Gene in Patients With Systematic Lupus Erythematosus (SLE)" is presented. (ebscohost.com)
  • Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. (tripdatabase.com)
  • Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. (tripdatabase.com)
  • PubMed, Lupus, 2019 Oct;28(11):1337-1343. (sclero.org)
  • PubMed, Lupus, 2019 Dec 1:961203319890677. (sclero.org)
  • 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. (lahey.org)
  • What is Systematic Lupus Erythematosus (SLE)? (adam.com)
  • Mice deficient in FcγRIIb demonstrate hyperactive immune responses ( 3 ) and are prone to autoimmunity ( 2 ), particularly systematic lupus erythematosus (SLE) ( 4 ), but show increased resistance to bacterial infections ( 5 ). (pnas.org)
  • Not all blistering eruptions that occur in patients with lupus erythematosus represent bullous systemic lupus erythematosus as defined above. (medscape.com)
  • These efficacy data establish that patients with lupus on baseline therapy with HCQ are not universally protected from COVID-19. (sclero.org)
  • The severity of the kidney involvement can alter the survival rate of patients with lupus. (baycare.org)
  • As such, preconception counseling for patients with lupus should include the recommendation to avoid pregnancy until the disease has been quiescent for at least 6 months. (renalandurologynews.com)
  • Other causes of premature death in patients with lupus include kidney failure and infections. (emedicinehealth.com)
  • As seen in many patients with lupus, the hallmark "butterfly rash" appears. (emedicinehealth.com)
  • Evaluations of disease activity were made through completion of the SLE Disease Activity Index (SLEDAI), the British Isles Lupus Assessment Group (BILAG) disease activity index and the physician's global assessment (PGA) of SLE activity. (medicalnewstoday.com)
  • In the target population, over 90% of the patients had at least 1A or 1B British Isles Lupus Assessment Group (BILAG) organ involvement and approximately 70% had at least 1A or 2B BILAG organ involvement. (nice.org.uk)
  • The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. (wiley.com)
  • 2.0 µg/ml) subsequently experienced a clinically relevant clotting event, in some cases in the absence of antiphospholipid antibodies or lupus anticoagulant. (medscape.com)
  • Third, although positive test results for antiphospholipid antibodies and lupus anticoagulant can predict lupus-associated disability, [ 1 ] routine tests that reliably predict clotting events in these individuals have not been established. (medscape.com)
  • Neuropsychiatric and extra-cerebral involvement, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) damage indexes, antiphospholipid antibodies and hyperhomocysteinemia were recorded for all the patients. (redorbit.com)
  • 3.4 Adult patients (aged 18 years or older) who met the American College of Rheumatology criteria for systemic lupus erythematosus and had active autoantibody-positive disease and a SELENA-SLEDAI score of 6 or more at screening were eligible for enrolment in the BLISS trials. (nice.org.uk)
  • Patients and Method: We studied 117 patients' files with systemic lupus erythematosus aged 12 to 73 years old, who fulfilled the American College of Rheumatology (ACR)'s criteria. (scirp.org)
  • Systemic lupus erythematosis is an autoimmune disease of unknown etiology (1-3). (springer.com)
  • Systemic lupus erythematosus (SLE) is a serious autoimmune disease of unknown etiology that can affect several organs. (cdc.gov)
  • The timing and etiology of diastolic impairment in pediatric-onset systemic lupus erythematosus (SLE) are poorly understood. (tripdatabase.com)
  • The etiology of the autoimmune disorder systemic lupus erythematosus (SLE) remains poorly understood. (jneurosci.org)
  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder of complex etiology. (jneurosci.org)
  • Considering taking medication to treat systemic lupus erythematosus? (webmd.com)
  • Echocardiographic Assessment of Diastolic Function in Children with Incident Systemic Lupus Erythematosus. (tripdatabase.com)
  • Association of Childhood Abuse with Incident Systemic Lupus Erythematosus in Adulthood in a Longitudinal Cohort of Women. (tripdatabase.com)
  • Increased risk of systemic lupus erythematosus in 29,000 patients with biopsy-verified celiac disease. (epnet.com)
  • Treatments for systemic lupus erythematosus (lupus) have improved dramatically in recent decades, giving doctors more choices in how to manage the disease. (nih.gov)
  • The aim of current treatments for systemic lupus erythematosus is to control and ease symptoms. (nice.org.uk)
  • Neuropsychiatric systemic lupus erythematosus or NPSLE refers to the neurological and psychiatric manifestations of systemic lupus erythematosus. (wikipedia.org)
  • Most of the patients had a range of manifestations of systemic lupus erythematosus, mainly involving mucocutaneous, immunological and/or musculoskeletal damage. (nice.org.uk)
  • Special article: the 1982 revised criteria for the classification of systemic lupus erythematosus. (springer.com)
  • Fries JF: The clinical aspects of systemic lupus erythematosus. (springer.com)
  • Heterogeneity of immunoregulatory T cell subsets in systemic lupus erythematosus: correlation with clinical features. (springer.com)
  • Authoritative and practical, Systemic Lupus Erythematosus: Methods and Protocols appeals to biomedical and clinical scientists in a number of pathology disciplines at the doctoral and post-doctoral level. (springer.com)
  • During the highly contagious 5- to 10-day incubation phase of the virus, patients often show no symptoms or have mild fevers and influenza-like symptoms, followed by about 5 days of viremia correlating with the presentation of systemic clinical symptoms. (cmaj.ca)
  • The term lupus has been used to identify a number of immune diseases that have similar clinical presentations and laboratory features, but SLE is the most common type of lupus . (healthline.com)
  • Bacteremia in systemic lupus erythematosus patients from RELESSER: risk factors, clinical and microbiological characteristics and outcomes. (tripdatabase.com)
  • Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by antibodies to nuclear and cytoplasmic antigens, multisystem inflammation, protean clinical manifestations, and a relapsing and remitting course. (medscape.com)
  • Although the lupus band appears to colocalize with type VII collagen, the noncollagenous-1 (NC1) domain of this protein does not represent the target antigen for circulating antibodies in systemic lupus erythematosus patients without clinical blistering. (medscape.com)
  • Linking a psychosocial stress intervention with clinical measures of stress in African American lupus patients will assess the utility of this method in reducing perceived stress, and provide the necessary preliminary steps toward future investigations of potential mechanisms. (pfizer.com)
  • Systemic Lupus Erythematosus (SLE) is the prototypical autoimmune disease, characterized by an extreme variety of anti-nuclear antibodies and by different clinical presentations. (frontiersin.org)
  • Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? (bmj.com)
  • 2010) Pregnancy and Systemic Lupus Erythematosus: Review of Clinical Features and Outcome of 51 Pregnancies at a Single Institution. (scirp.org)
  • Cortés-Hernández, J., Ordi-Ros, J. and Paredes, F. (2002) Clinical Predictors of Fetal and Maternal Outcome in Systemic Lupus Erythematosus: A Prospective Study of 103 Pregnancies. (scirp.org)
  • Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterised by the production of IgG autoantibodies that are specific for self-antigens, such as DNA, nuclear proteins and certain cytoplasmic components, in association with a diverse array of clinical manifestations. (genome.jp)
  • Aim: To determine the clinical and immunological characteristics of patients with systemic erythematosus lupus in Abidjan. (scirp.org)
  • Researchers know that lupus autoantibodies are present up to five years prior to development of clinical disease, with onset occurring once genetic load is sufficient and immune triggers present themselves. (empr.com)
  • To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials. (wiley.com)
  • SIGNIFICANCE STATEMENT Although clinical manifestations of neuropsychiatric lupus are well recognized, the underlying molecular-cellular alterations have been difficult to determine. (jneurosci.org)
  • Attention has been particularly focused on young lupus mice including mice of one week old, before the onset of clinical disease. (bl.uk)
  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ systems, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ failure with episodes of relapses and remissions. (digitaljournal.com)
  • Subset specificity of antilymphocyte antibodies in systemic lupus erythematosus. (springer.com)
  • However, since the ANA test can sometimes be positive in people who do not have lupus, your doctor may order follow-up blood tests to look for other types of antibodies. (womenshealthmag.com)
  • The autoantibody repertoire of systemic lupus erythematosus can include nonpathogenic and pathogenic anti-BMZ antibodies. (medscape.com)
  • Patients with nonbullous systemic lupus erythematosus often have circulating antibodies to various components of the BMZ (including bullous pemphigoid antigens 1 and 2), which may have a role in formation of the lesional lupus band (ie, granular antibody deposition at the BMZ in normal-appearing skin). (medscape.com)
  • In patients with bullous systemic lupus erythematosus, antibodies directed at the BMZ likely mediate the blistering phenotype by directly interfering with adhesive connections at the dermoepidermal junction and through induction of complement-dependent inflammation that leads to tissue injury and dermoepidermal separation. (medscape.com)
  • In patients with systemic lupus erythematosus without vesiculobullous eruptions, an increase of circulating antitype VII collagen antibodies may precede the onset of type 1 bullous systemic lupus erythematosus. (medscape.com)
  • [ 11 ] In type 1 bullous systemic lupus erythematosus (which accounts for most cases), antibodies against type VII collagen may weaken or block anchoring fibril-mediated connections between the lamina densa of the basement membrane and the papillary dermis. (medscape.com)
  • Many relapses of systemic lupus erythematosus (SLE) are preceded by a rise in antibodies against double-stranded DNA (anti-dsDNA). (nih.gov)
  • Systemic lupus erythematosus (SLE) is when the immune system makes antibodies that attack the body's healthy cells and tissue. (denverhealth.org)
  • 1 The syndrome is associated with the presence of anticardiolipin antibodies or lupus anticoagulant, or both. (cmaj.ca)
  • Initial screening for lupus should include testing for anti-nuclear antibodies. (renalandurologynews.com)
  • High risk: Procainamide (antiarrhythmic) Hydralazine (antihypertensive) Moderate risk: Quinidine (antiarrhythmic) Low to Very Low Risk: Infliximab anti (TNF-α) Etanercept anti (TNF-α) Isoniazid (antibiotic) Minocycline (antibiotic) Pyrazinamide (antibiotic) D-Penicillamine (anti-inflammatory) Carbamazepine (anticonvulsant) Oxcarbazepine (anticonvulsant) Phenytoin (anticonvulsant) Propafenone (antiarrhythmic) Chlorpromazine (antipsychotic) Minoxidil (antihypertensive vasodilator) Antinuclear antibodies are usually positive in drug-induced Lupus. (wikipedia.org)
  • Furthermore, Anti-Histone antibodies can also be positive in drug-induced lupus. (wikipedia.org)
  • citation needed] Anti-Histone antibodies are positive in up to 95% of patients with drug induced lupus. (wikipedia.org)
  • Your doctor will begin by reviewing your symptoms, your medical history and your exposure to factors that can trigger lupus flares. (womenshealthmag.com)
  • One of the goals of controlling mild to moderate lupus symptoms is to prevent flares. (uwhealth.org)
  • Most recent data suggest that the incidence of lupus flares is not increased during pregnancy. (renalandurologynews.com)
  • Some common triggers for lupus flares include infections, stress, pregnancy, sunlight, and starting or stopping a new medication. (emedicinehealth.com)
  • Lupus flares are unpredictable and there is no way to tell how long they will last. (emedicinehealth.com)
  • Is there anyone that has Lupus with brain involvement? (drugs.com)
  • Successful treatment with hydroxychloroquine for systemic lupus erythematosus with cutaneous involvement accompanied by a xanthomatous reaction. (sclero.org)
  • Children with lupus can have a large degree of kidney involvement. (baycare.org)
  • Neuropsychiatric involvement in systemic lupus erythematosus (SLE) is considered as one of the major manifestations of the disease. (neurology.org)
  • The origin of the defects leading to pathogenicity in systemic lupus erythematosus (SLE), an autoimmune disorder characterised by multi-system involvement, female preference, B-cell hyperactivity, autoantibody production and immune complex deposition, is still controversial. (bl.uk)
  • The production of autoantibodies represents a central feature of systemic lupus erythematosus. (medscape.com)
  • The injection of n-hexadecane, pristane, incomplete Freund's adjuvant (IFA), or the adjuvant oil squalene results in lupus-related specific autoantibodies in an animal model. (greenmedinfo.com)
  • Conclusion: Systemic lupus erythematosus of Ivorian black subject is characterised by high prevalence of autoantibodies, mostly Anti-RNP. (scirp.org)
  • Systemic lupus erythematosus [SLE (OMIM 152700)] is a chronic autoimmune disease characterized by circulating autoantibodies to nuclear antigens. (pnas.org)
  • We report that sera of a subset of lupus patients contain autoantibodies directed at regulatory brain cytoplasmic (BC) RNAs. (jneurosci.org)
  • Systemic lupus erythematosus (SLE) 4 is characterized by the production of multiple autoantibodies. (jimmunol.org)
  • Ankylosing spondylitis (AS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are the most common rheumatic diseases dealt with rheumatologists in Taiwan. (centerwatch.com)
  • Development and Validation of a microRNA Panel to Differentiate between Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus and Controls. (tripdatabase.com)
  • Rheumatoid factor and Extractable nuclear antigen Ab (especially the presence of Sm Antibody) assist to differentiate SLE from other systemic rheumatic diseases. (edu.au)
  • These medicines are used if you have severe lupus that is affecting the nervous system, kidney or other organs. (medlineplus.gov)
  • Barber CE and Barnabe C (2012) Another consequence of severe lupus: invasive fungal disease. (els.net)
  • Severe lupus can cause harm to organs and other serious problems. (massgeneral.org)
  • Each person with systemic lupus erythematosus (lupus) has slightly different symptoms that can range from mild to severe. (nih.gov)
  • In this study, theere are 90 severe systemic lupus erythematosus that were. (ebscohost.com)
  • Baseline use of hydroxychloroquine (HCQ) in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. (sclero.org)
  • Lupus affects each individual differently and the effects of the illness range from mild to severe. (baycare.org)
  • In a patient known to have lupus, it is sometimes difficult to differentiate a lupus flare during pregnancy from the onset of superimposed severe preeclampsia. (renalandurologynews.com)
  • The symptoms of systemic lupus erythematosus (SLE) vary from mild to severe and debilitating. (portsmouthhospital.com)
  • While these symptoms are similar to those of systemic lupus erythematosus, they are generally not as severe unless they are ignored which leads to more harsh symptoms, and in some reported cases, death. (wikipedia.org)
  • further RCTs assessing the efficacy and safety of mycophenolate in people with non-renal systemic lupus erythematosus are needed. (nice.org.uk)
  • Low quality data in non-renal systemic lupus erythematosus suggest some effectiveness for mycophenolate mofetil. (nice.org.uk)
  • Immune complexes comprising autoantibody and self-antigen is deposited particulary in the renal glomeruli and mediate a systemic inflammatory response by activating complement or via Fc{gamma}R-mediated neutrophil and macrophage activation. (genome.jp)
  • According to the Lupus Foundation of America, at least 1.5 million Americans are living with diagnosed lupus. (healthline.com)
  • The Lupus Foundation of America estimates about 1.5 million Americans and at least 5 million people worldwide have some form of lupus, making it more prevalent than HIV, AIDS, sickle cell anemia, and multiple sclerosis combined. (emedicinehealth.com)
  • Pincus T: Studies regarding a possible function for viruses in the pathogenesis of systemic lupus erythematosus. (springer.com)
  • Metabolism as a key regulator in the pathogenesis of systemic lupus erythematosus. (tripdatabase.com)
  • This research protocol will evaluate subjects with systemic lupus erythematosus (SLE) and their relatives to study the pathogenesis and natural history of the disease and the mechanisms leading to enhanced organ damage. (clinicaltrials.gov)
  • Vaccine adjuvants can contribute to the pathogenesis of autoimmune diseases such as lupus. (greenmedinfo.com)
  • Our findings reveal that CR2 is a likely susceptibility gene for human lupus at 1q32.2, extending previous studies suggesting that CR2 participates in the pathogenesis of systemic lupus erythematosus. (pnas.org)
  • Cellular RNA dysregulation may thus be a contributing factor in the pathogenesis of neuropsychiatric lupus. (jneurosci.org)
  • Lupus anticoagulant and Cardiolipin Ab may also predict complications of disease. (edu.au)
  • The laboratory findings were consistent with a lupus anticoagulant. (cmaj.ca)
  • More recently, the Systemic Lupus International Collaborating Clinics Classification Criteria for SLE have also been developed. (rheumatology.org)
  • The most recent criteria were published by the Systemic Lupus International Collaborating Clinics (SLICC) in 2012. (uspharmacist.com)
  • The three main categories of lesions are chronic cutaneous (discoid) lupus, subacute cutaneous lupus, and acute cutaneous lupus. (wikipedia.org)
  • People with discoid lupus may exhibit thick, red scaly patches on the skin. (wikipedia.org)
  • This is called discoid lupus. (medlineplus.gov)
  • Mucocutaneous lesions occur in 80% of patients, including acute utaneous lupus (particularly malar rash), chronic cutaneous lupus most commonly discoid lupus erythematosus, as evident in this patient), oral ulcers, and non-scarring alopecia. (rheumatology.org)
  • Some people develop a form of lupus that involves only the skin, called cutaneous lupus or discoid lupus erythematosus. (womenshealthmag.com)
  • Discoid lupus erythematosus. (adam.com)
  • It is different from discoid lupus erythematosus (DLE) , which is a skin disease. (veterinarypartner.com)
  • As yet unrecognized factors may play a role in the development of a xanthomatous reaction in discoid lupus erythematosus. (sclero.org)
  • Discoid lupus, pictured here, is a chronic rash typically found on the face and scalp that has characteristic skin findings and is generally negative on antinuclear antibody tests. (empr.com)
  • Discoid lupus erythematosus is described as usually being limited to the skin and may, or may not, present with a positive anti-nuclear antibody (ANA) test. (chiro.org)
  • citation needed] Anti-histone antibody Lupus erythematosus Hydralazine Discoid lupus erythematosus List of cutaneous conditions Rubin, Robert L. (2005-02-04). (wikipedia.org)
  • [6] Lupus is Latin for "wolf": the disease was so-named in the 13th century as the rash was thought to appear like a wolf's bite. (wikipedia.org)
  • Acute cutaneous lupus manifests as a rash. (wikipedia.org)
  • While drug-induced lupus may cause rash, arthritis and fever that appear similar to the systemic form of lupus, it tends to be milder. (womenshealthmag.com)
  • A type of cutaneous lupus that produces a potentially scarring disc-shaped rash on the face, scalp, or ears. (adam.com)
  • Babies with neonatal lupus are born with skin rash, liver problems, and low blood counts and may develop heart problems. (adam.com)
  • Rash on the face of a 50-year-old female patient with systemic lupus erythematosus (SLE). (sciencephoto.com)
  • Also called the "malar rash," the "butterfly rash" typically seen in lupus appears across the nose and cheeks in a butterfly-shape. (emedicinehealth.com)
  • Systemic lupus erythematosus (SLE) is a chronic inflammatory disease of unknown cause that can affect the skin, joints, kidneys, lungs, nervous system, serous membranes and/or other organs of the body. (els.net)
  • In children, lupus often attacks the kidneys. (massgeneral.org)
  • Systemic lupus erythematosus (SLE) is an autoimmune disease affecting mostly joints, skin, blood vessels, heart, lungs, kidneys, liver, and nervous system, in which the immune system attacks tissues and cells leading to inflammation and damage ( 1 ). (frontiersin.org)
  • Systemic lupus erythematosus (SLE) is a long-term autoimmune disorder that may affect the skin, joints, kidneys, brain and other organs. (empr.com)
  • Systemic lupus erythematosus is a chronic autoimmune disorder primarily involving connective tissue. (patientslikeme.com)
  • Systemic lupus erythematosus (SLE) is an autoimmune disorder. (adam.com)
  • Lupus is an autoimmune disorder, which means the body's immune system attacks its own healthy cells and tissues. (baycare.org)
  • Lupus, or Systemic Lupus Erythematosus (SLE), is not an infectious disease but an autoimmune disorder. (emedicinehealth.com)
  • Drug-induced lupus erythematosus is an autoimmune disorder caused by chronic use of certain drugs. (wikipedia.org)
  • This article is about a type of lupus. (wikipedia.org)
  • Systemic lupus erythematosus (SLE), is the most common type of lupus. (cdc.gov)
  • SLE is the most common type and is the type of lupus that can lead to serious systemic complications. (adam.com)
  • About 10% of people with this type of lupus go on to develop SLE. (adam.com)
  • This topic focuses on systemic lupus erythematosus (SLE), the most common and most serious type of lupus. (uwhealth.org)
  • The target population is adults with active autoantibody-positive systemic lupus erythematosus with evidence for serological disease activity (defined as positive anti-double-stranded DNA and low complement) and a Safety of Estrogen in Lupus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of greater than or equal to 10. (nice.org.uk)
  • Belimumab is a monoclonal antibody, prescribed for active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. (medindia.net)
  • Lupus also affects more African Americans, Asian Americans, Hispanics, and American Indians than whites. (massgeneral.org)
  • Anyone can get lupus, but it most often affects women. (nih.gov)
  • Reduced risk of ovarian failure may be particularly important because systemic lupus erythematosus affects women of child bearing potential. (nice.org.uk)
  • Because lupus affects different people in different ways, it can be hard to diagnose. (uwhealth.org)
  • Copenhagen, Denmark, Friday 12 June 2009: 92.8% of patients with systemic lupus erythematosus (SLE) suffer anxiety and depression which significantly affects both their physical and emotional quality of life (QoL), according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. (redorbit.com)
  • Lupus affects more African-Americans, Asian Americans, Latinos, and American Indians than white Americans. (baycare.org)
  • Systemic Lupus Erythematosus (henceforth referred to as S.L.E.) is a multi-symptom, multi-organ connective tissue disease that primarily affects women of child-bearing age. (healthy.net)
  • This condition is called drug-induced lupus. (encyclopedia.com)
  • Drug-induced lupus usually disappears after the patient stops taking the particular medication. (encyclopedia.com)
  • Another form of lupus follows exposure to certain drugs (drug-induced lupus) including procainamide and hydralazine. (womenshealthmag.com)
  • Drug induced lupus is a condition characterized by lupus-like symptoms that are a result of an adverse reaction to a prescription drug. (chiro.org)
  • Drug-induced lupus appears to be the only non-gender biased form of the disease, with men being as equally susceptible as women. (chiro.org)
  • Signs and symptoms of drug-induced lupus erythematosus include the following:[citation needed] Joint pain (arthralgia) and muscle pain (myalgia) Fatigue Serositis-inflammation of the tissues lining the heart and lungs. (wikipedia.org)
  • citation needed] The processes that lead to drug-induced lupus erythematosus are not entirely understood. (wikipedia.org)
  • Symptoms of drug-induced lupus erythematosus generally disappear days to weeks after medication use is discontinued. (wikipedia.org)
  • Systemic lupus erythematosus ( SLE ), also known simply as lupus , is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. (wikipedia.org)
  • Systemic lupus erythematosus (also called lupus or SLE) is a disease in which a person's immune system attacks and injures the body's own organs and tissues. (encyclopedia.com)
  • Lupus is thought to develop when your body's immune system mistakenly attacks the body's own tissues rather than protecting them from outside invaders. (womenshealthmag.com)
  • Systemic lupus erythematosus (SLE) is a problem with the immune system. (epnet.com)
  • Systemic lupus erythematosus (SLE or lupus) is a disease that causes your body's immune system to attack its own cells and tissues. (massgeneral.org)
  • Lupus occurs when the immune system, which normally helps protect the body from infection and disease, attacks different parts of the body. (nih.gov)
  • With lupus and other autoimmune diseases, the immune system does not work properly. (adam.com)
  • The therapeutic strategies today for treatment of lupus disease are mainly based on a general suppression of the immune system with uncertainty about their long term effects being beneficial or rather harmful to the patients. (bl.uk)
  • The objective of this study is to evaluate and compare efficacy of 3 dose levels of PF-04236921 to placebo in subjects with generalized lupus using a measure called the Systemic Lupus Erythematosus (SLE) Responder Index. (pfizer.com)
  • The primary outcome of both studies was the response rate at week 52 compared with baseline, assessed with the Systemic Lupus Erythematosus Responder Index (SRI). (nice.org.uk)
  • Despite the high prevalence of cardiovascular disease among patients with systemic lupus erythematosus , the relationship between age, blood pressure, and blood pressure variability (BPV) is not well understood. (tripdatabase.com)
  • Most of the studies present in the literature show a high prevalence, and incidence, of new cases of hypothyroidism and autoimmune thyroiditis (AT) in systemic lupus erythematosus (SLE) patients, overall in female gender. (frontiersin.org)
  • Systemic lupus erythematosis (SLE) is an immunologic disorder affecting primarily women, with a female:male ratio in adults of approximately 10:1.The prevalence is approximately 1 in 300 reproductive age women, and as such is encountered on occasion among pregnant patients. (renalandurologynews.com)
  • For the group of diseases known as "lupus", see Lupus erythematosus . (wikipedia.org)
  • There are many autoimmune diseases, including systemic lupus erythematosus (SLE). (healthline.com)
  • The survival rate in Systemic Lupus Erythematosus (SLE) exceeds 90% at 10 years but health status is severely impaired and comparable with that of advanced cardiac or respiratory diseases. (centerwatch.com)
  • An SLE death was defined as any death of a U.S. resident coded with an underlying cause of death of systemic lupus erythematosus ( International Classification of Diseases, Ninth Revision, code 710.0). (cdc.gov)
  • Systemic lupus erythematosus is associated with many other autoimmune diseases, and autoimmune thyroid disorders (AITD) too ( 7 , 8 ). (frontiersin.org)
  • However, care for the patient with lupus and other autoimmune diseases has changed dramatically over the past few decades, with five year survival improving from 50% in the 1960s to 95% today. (empr.com)
  • Polygenic autoimmune diseases, such as systemic lupus erythematosus (SLE), are a significant cause of morbidity and mortality worldwide. (pnas.org)
  • The BILAG disease activity index evaluates systemic lupus erythematosus (SLE) activity in 8 organ systems, using a separate alphabetic score (A to E) assigned to each organ system defined as follows. (clinicaltrials.gov)
  • Similarly, subacute cutaneous lupus manifests as red, scaly patches of skin but with distinct edges. (wikipedia.org)
  • Neonatal lupus. (adam.com)
  • But there are other types of lupus, such as discoid or cutaneous lupus, drug-induced systemic lupus, and neonatal lupus. (uwhealth.org)
  • Subfertility treatment in women with systemic lupus erythematosus. (biomedsearch.com)
  • Maternal Hypertensive Disorders in Pregnant Women With Systemic Lupus Erythematosus and Future Cardiovascular Outcomes. (harvard.edu)
  • Systemic lupus erythematosus is a chronic autoimmune condition that causes inflammation in the body's tissues. (nice.org.uk)
  • Systemic lupus is a chronic autoimmune disease characterised by its phenotypic heterogeneity. (unboundmedicine.com)
  • However all women with lupus who get pregnant are considered to have a "high risk pregnancy. (cdc.gov)
  • Learn more about pregnancy and lupus . (cdc.gov)
  • Systemic lupus erythematosus in pregnancy brings risks for the mother, and possible harm to the fetus if the disease is treated. (bmj.com)
  • Pregnancy and systemic lupus erythematosus in black African women: about 10 cases in Libreville (Gabon). (scirp.org)
  • We've included, systemic lupus erythematosus women carrying a pregnancy during the period of the study. (scirp.org)
  • Le Thi Huong, D., Wechsler, B. and Piette, J.C. (1994) French Register of Lupus in Pregnancy: The Evaluation. (scirp.org)
  • Medications should be reviewed for their teratogenic potential, but many medications used to control lupus should not be stopped before or during pregnancy, as the benefits of disease control often outweigh the theoretical concerns. (renalandurologynews.com)
  • A genomic region on distal mouse chromosome 1 and its syntenic human counterpart 1q23-42 show strong evidence of harboring lupus susceptibility genes. (pnas.org)
  • A positional candidate gene at 1q32.2, complement receptor 2 ( CR2 ), is also a candidate in the murine Sle1c lupus susceptibility locus. (pnas.org)
  • To explore its role in human disease, we analyzed 1,416 individuals from 258 Caucasian and 142 Chinese lupus simplex families and demonstrated that a common three-single-nucleotide polymorphism CR2 haplotype (rs3813946, rs1048971, rs17615) was associated with lupus susceptibility ( P = 0.00001) with a 1.54-fold increased risk for the development of disease. (pnas.org)
  • Human chromosome 1q21-43 is syntenic to the distal end of mouse chromosome 1, where a recessive locus termed Sle1 has been strongly associated with lupus susceptibility ( 9 ). (pnas.org)
  • Syntenic conservation in susceptibility intervals between mice and humans suggests the possibility that the same genes may confer risk for both murine and human lupus. (pnas.org)
  • Cr2 is a major positional candidate gene of the murine Sle1c lupus susceptibility interval ( 11 ). (pnas.org)
  • We report here linkage with lupus susceptibility in humans at 1q32.2 and provide compelling evidence that CR2 is an important gene in that region. (pnas.org)
  • Photosensitive systemic lupus erythematosus (SLE) rashes typically occur on the face or extremities, which are sun-exposed regions. (medscape.com)
  • These syndromes encompass disorders of the central and peripheral nervous systems: Each of the 19 syndromes are also stand-alone diagnoses, which can occur with or without lupus. (wikipedia.org)
  • Lupus can occur at any age but is most common in women, particularly of non-European descent. (redorbit.com)
  • Epileptic seizures can be a primary event resulting from the direct effect of active SLE manifestation in the CNS or occur independently of lupus activity itself, being associated with CNS infections, uremia, hypertension, or electrolytic disturbance. (neurology.org)
  • Since the stage of development at which these defects occur is not clearly understood, efforts have been devoted to analysis of lymphocytes from lupus mice at different ages, in relation to the disease activity. (bl.uk)
  • A temporary and mild form of lupus caused by certain prescription medications. (adam.com)
  • Unlike arthritis, there is only one form of lupus. (emedicinehealth.com)